1
|
Nicolas G, Zaréa A, Lacour M, Quenez O, Rousseau S, Richard AC, Bonnevalle A, Schramm C, Olaso R, Sandron F, Boland A, Deleuze JF, Andriuta D, Anthony P, Auriacombe S, Balageas AC, Ballan G, Barbay M, Béjot Y, Belliard S, Benaiteau M, Bennys K, Bombois S, Boutoleau-Bretonnière C, Branger P, Carlier J, Cartz-Piver L, Cassagnaud P, Ceccaldi MP, Chauviré V, Chen Y, Cogez J, Cognat E, Contegal-Callier F, Corneille L, Couratier P, Cretin B, Crinquette C, Dauriat B, Dautricourt S, de la Sayette V, de Liège A, Deffond D, Demurger F, Deramecourt V, Derollez C, Dionet E, Doco Fenzy M, Dumurgier J, Dutray A, Etcharry-Bouyx F, Formaglio M, Gabelle A, Gainche-Salmon A, Godefroy O, Graber M, Gregoire C, Grimaldi S, Gueniat J, Gueriot C, Guillet-Pichon V, Haffen S, Hanta CR, Hardy C, Hautecloque G, Heitz C, Hourregue C, Jonveaux T, Jurici S, Koric L, Krolak-Salmon P, Lagarde J, Lanoiselée HM, Laurens B, Le Ber I, Le Guyader G, Leblanc A, Lebouvier T, Levy R, Lippi A, Mackowiak MA, Magnin E, Marelli C, Martinaud O, Maureille A, Migliaccio R, Milongo-Rigal E, Mohr S, Mollion H, Morin A, Nivelle J, Noiray C, Olivieri P, Paquet C, Pariente J, Pasquier F, Perron A, Philippi N, Planche V, Pouclet-Courtemanche H, Rafiq M, Rollin-Sillaire A, Roué-Jagot C, Saracino D, Sarazin M, Sauvée M, Sellal F, Teichmann M, Thauvin C, Thomas Q, Tisserand C, Turpinat C, Van Damme L, Vercruysse O, Villain N, Wagemann N, Charbonnier C, Wallon D. Assessment of Mendelian and risk-factor genes in Alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening. Genet Med 2024; 26:101082. [PMID: 38281098 DOI: 10.1016/j.gim.2024.101082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 01/17/2024] [Accepted: 01/19/2024] [Indexed: 01/29/2024] Open
Abstract
PURPOSE To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD). METHODS We included 700 patients in a prospective study and performed exome sequencing. A panel of 28 Mendelian and 6 risk-factor genes was interpreted and returned to patients. We built a framework for risk variant interpretation and risk gradation and assessed the detection rates among early-onset AD (EOAD, age of onset (AOO) ≤65 years, n = 608) depending on AOO and pedigree structure and late-onset AD (66 < AOO < 75, n = 92). RESULTS Twenty-one patients carried a LP/P variant in a Mendelian gene (all with EOAD, 3.4%), 20 of 21 affected APP, PSEN1, or PSEN2. LP/P variant detection rates in EOAD ranged from 1.7% to 11.6% based on AOO and pedigree structure. Risk factors were found in 69.5% of the remaining 679 patients, including 83 (12.2%) being heterozygotes for rare risk variants, in decreasing order of frequency, in TREM2, ABCA7, ATP8B4, SORL1, and ABCA1, including 5 heterozygotes for multiple rare risk variants, suggesting non-monogenic inheritance, even in some autosomal-dominant-like pedigrees. CONCLUSION We suggest that genetic screening should be proposed to all EOAD patients and should no longer be prioritized based on pedigree structure.
Collapse
Affiliation(s)
- Gaël Nicolas
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France.
| | - Aline Zaréa
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Morgane Lacour
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Olivier Quenez
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Stéphane Rousseau
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Anne-Claire Richard
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Antoine Bonnevalle
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France; Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Catherine Schramm
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Robert Olaso
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Florian Sandron
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Anne Boland
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Jean-François Deleuze
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Daniela Andriuta
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Pierre Anthony
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France
| | - Sophie Auriacombe
- Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Bordeaux, France
| | | | | | - Mélanie Barbay
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Yannick Béjot
- Department of Neurology, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Serge Belliard
- Unité de recherche 1077 INSERM-EPHE-UNICAEN Neuropsychologie & Imagerie de la Mémoire Humaine (NIMH), Caen, France; Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Marie Benaiteau
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Karim Bennys
- Memory Ressources Research Center, Department of Neurology, University Hospital of Montpellier, Montpellier, France
| | - Stéphanie Bombois
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Pierre Branger
- Department of Neurology, Caen University Hospital, Caen, France
| | - Jasmine Carlier
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Leslie Cartz-Piver
- Memory Ressources Research Center, Department of Neurology, University Hospital of Limoges, France Inserm U1094, IRD U270, EPIMACT, Université of Limoges, Limoges, France
| | | | - Mathieu-Pierre Ceccaldi
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | - Valérie Chauviré
- CMRR, CRMR Neurogénétique, Service de Neurologie, CHU d'ANGERS, Angers, France
| | - Yaohua Chen
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Julien Cogez
- Department of Neurology, Caen University Hospital, Caen, France
| | - Emmanuel Cognat
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | | | - Léa Corneille
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | | | - Benjamin Cretin
- CMRR d'Alsace, Service de Neurologie, CHU Strasbourg, Strasbourg, France
| | | | - Benjamin Dauriat
- Service de Génétique Médicale, Hopital Mère-Enfant, CHU Limoges, Limoges, France
| | - Sophie Dautricourt
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Vincent de la Sayette
- Department of Neurology, Caen University Hospital, Caen, France; Normandie UNIV, UNICAEN, PSL Research University, EPHE, INSERM, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, Caen, France
| | - Astrid de Liège
- Service de Neurologie, APHP, Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France
| | - Didier Deffond
- CMRR Clermont-Ferrand, Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Vincent Deramecourt
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | | | - Elsa Dionet
- CMRR Clermont-Ferrand, Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Martine Doco Fenzy
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France; CHU Nantes, Service de Génétique, Nantes, France; CHU Reims, Service de Génétique, Reims, France
| | - Julien Dumurgier
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | - Anaïs Dutray
- Service de Neurologie, Centre Hospitalier Perpignan, Perpignan, France
| | | | - Maïté Formaglio
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Audrey Gabelle
- Memory Ressources Research Center, Department of Neurology, University Hospital of Montpellier, Montpellier, France
| | - Anne Gainche-Salmon
- Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Olivier Godefroy
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Mathilde Graber
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Chloé Gregoire
- CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | - Stephan Grimaldi
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | - Julien Gueniat
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Claude Gueriot
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | | | - Sophie Haffen
- Centre mémoire Recherche Ressources, Service de Neurologie, CHU Besançon, Besançon, France
| | - Cezara-Roxana Hanta
- Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Clémence Hardy
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | | | - Camille Heitz
- Institut du cerveau Trocadero, Paris, France; Neurology Department, Hôpital Universitaire de Nîmes, Nîmes, France
| | - Claire Hourregue
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Thérèse Jonveaux
- Centre Mémoire de Ressources et de Recherche de Lorraine Service de Neurologie CHRU Nancy, Nancy, France; Laboratoire 2LPN EA 7489 Université de Lorraine, Nancy, France
| | - Snejana Jurici
- Consultation Mémoire, Service de Gériatrie, Centre Hospitalier Perpignan, Perpignan, France
| | - Lejla Koric
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France; Aix-Marseille Univ, UMR 7249, CNRS, Centrale Marseille, Institut Fresnel, Marseille, France
| | - Pierre Krolak-Salmon
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Julien Lagarde
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | | | - Brice Laurens
- CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | - Isabelle Le Ber
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Amélie Leblanc
- Consultations neurologiques, HIA Clermont-Tonnerre, Brest, France; Service de neurologie, CHU Cavale-Blanche, Brest, France
| | - Thibaud Lebouvier
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Richard Levy
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Anaïs Lippi
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | | | - Eloi Magnin
- Laboratoire de neuroscience, Université de Franche-Comté UFC et Service de Neurologie, CMRR, CHU Besançon, Besançon, France
| | - Cecilia Marelli
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | - Olivier Martinaud
- Department of Neurology, Caen University Hospital, Caen, France; Normandie UNIV, UNICAEN, PSL Research University, EPHE, INSERM, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, Caen, France
| | | | - Raffaella Migliaccio
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Emilie Milongo-Rigal
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Sophie Mohr
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Hélène Mollion
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Alexandre Morin
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France; Département de Psychiatrie, Centre Hospitalier du Rouvray, Université de Rouen, 76000, Sotteville-lès-Rouen, France
| | | | - Camille Noiray
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Pauline Olivieri
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Claire Paquet
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | - Jérémie Pariente
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), INSERM-University of Toulouse Paul Sabatier, Toulouse, France
| | - Florence Pasquier
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Alexandre Perron
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France
| | - Nathalie Philippi
- CMRR d'Alsace, Service de Neurologie, CHU Strasbourg, Strasbourg, France
| | - Vincent Planche
- Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Bordeaux, France; CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | | | - Marie Rafiq
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), INSERM-University of Toulouse Paul Sabatier, Toulouse, France
| | | | - Carole Roué-Jagot
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Dario Saracino
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Marie Sarazin
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Mathilde Sauvée
- Centre Mémoire de Ressources et de Recherche, Pôle PReNeLe, CHU Grenoble Alpes CS 10226, 38043 Grenoble Cedex 9, France; Unité de recherche mixte Université Grenoble Alpes/Université Savoie Montblanc, CNRS UMR 5115, Laboratoire de Psychologie et Neurocognition (LPNC), 38000 Grenoble, France
| | - François Sellal
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France; University of Strasbourg, Medicine Faculty, INSERM, U-1118, Strasbourg, France
| | - Marc Teichmann
- AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Christel Thauvin
- Genetics Center, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Quentin Thomas
- Department of Neurology, University Hospital of Dijon, University of Burgundy, Dijon, France; Genetics Center, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Camille Tisserand
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Cédric Turpinat
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | - Laurène Van Damme
- Service de Neurologie, Centre Hospitalier Perpignan, Perpignan, France
| | | | - Nicolas Villain
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Camille Charbonnier
- Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Biostatistics and CNRMAJ, F-76000 Rouen, France
| | - David Wallon
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| |
Collapse
|
2
|
Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J Neurol Neurosurg Psychiatry 2024:jnnp-2024-333467. [PMID: 38658136 DOI: 10.1136/jnnp-2024-333467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Accepted: 04/04/2024] [Indexed: 04/26/2024]
Abstract
BACKGROUND Among plasma biomarkers for Alzheimer's disease (AD), pTau181 and pTau217 are the most promising. However, transition from research to routine clinical use will require confirmation of clinical performance in prospective cohorts and evaluation of cofounding factors. METHOD pTau181 and pTau217 were quantified using, Quanterix and ALZpath, SIMOA assays in the well-characterised prospective multicentre BALTAZAR (Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk) cohort of participants with mild cognitive impairment (MCI). RESULTS Among participants with MCI, 55% were Aβ+ and 29% developed dementia due to AD. pTau181 and pTau217 were higher in the Aβ+ population with fold change of 1.5 and 2.7, respectively. MCI that converted to AD also had higher levels than non-converters, with HRs of 1.38 (1.26 to 1.51) for pTau181 compared with 8.22 (5.45 to 12.39) for pTau217. The area under the curve for predicting Aβ+ was 0.783 (95% CI 0.721 to 0.836; cut-point 2.75 pg/mL) for pTau181 and 0.914 (95% CI 0.868 to 0.948; cut-point 0.44 pg/mL) for pTau217. The high predictive power of pTau217 was not improved by adding age, sex and apolipoprotein E ε4 (APOEε4) status, in a logistic model. Age, APOEε4 and renal dysfunction were associated with pTau levels, but the clinical performance of pTau217 was only marginally altered by these factors. Using a two cut-point approach, a 95% positive predictive value for Aβ+ corresponded to pTau217 >0.8 pg/mL and a 95% negative predictive value at <0.23 pg/mL. At these two cut-points, the percentages of MCI conversion were 56.8% and 9.7%, respectively, while the annual rates of decline in Mini-Mental State Examination were -2.32 versus -0.65. CONCLUSIONS Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.
Collapse
Affiliation(s)
- Sylvain Lehmann
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
| | - Susanna Schraen-Maschke
- Université Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000, Lille, France
| | - Jean-Sébastien Vidal
- Université Paris Cité, EA 4468, APHP, Hospital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, F-75013, Paris, Île-de-France, France
| | - Constance Delaby
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau - Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Luc Buee
- Université Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000, Lille, France
| | - Frédéric Blanc
- Université de Strasbourg, Hôpitaux Universitaires de Strasbourg, Memory Resource and Research Centre of Strasbourg/Colmar, French National Centre for Scientific Research (CNRS), ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS)/Neurocrypto, F-67000, Strasbourg, France
| | - Claire Paquet
- Université Paris Cité, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, F-75010, Paris, France
| | - Bernadette Allinquant
- UMR-S1266, Université Paris Cité, Institute of Psychiatry and Neuroscience, Inserm, Paris, France
| | - Stéphanie Bombois
- Université Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000, Lille, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France
| | - Audrey Gabelle
- Université de Montpellier, Memory Research and Resources center, department of Neurology, Inserm INM NeuroPEPs team, F-34000, Montpellier, France
| | - Olivier Hanon
- Université Paris Cité, EA 4468, APHP, Hospital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, F-75013, Paris, Île-de-France, France
| |
Collapse
|
3
|
Schraen-Maschke S, Duhamel A, Vidal JS, Ramdane N, Vaudran L, Dussart C, Buée L, Sablonnière B, Delaby C, Allinquant B, Gabelle A, Bombois S, Lehmann S, Hanon O. The free plasma amyloid Aβ 1-42/Aβ 1-40 ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Aβ 1-42/Aβ 1-40 ratio. The BALTAZAR study. Neurobiol Dis 2024; 193:106459. [PMID: 38423192 DOI: 10.1016/j.nbd.2024.106459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 02/26/2024] [Accepted: 02/26/2024] [Indexed: 03/02/2024] Open
Abstract
BACKGROUND AND PURPOSE Blood-based biomarkers are a non-invasive solution to predict the risk of conversion of mild cognitive impairment (MCI) to dementia. The utility of free plasma amyloid peptides (not bound to plasma proteins and/or cells) as an early indicator of conversion to dementia is still debated, as the results of studies have been contradictory. In this context, we investigated whether plasma levels of the free amyloid peptides Aβ1-42 and Aβ1-40 and the free plasma Aβ1-42/Aβ1-40 ratio are associated with the conversion of MCI to dementia, in particular AD, over three years of follow-up in a subgroup of the BALTAZAR cohort. We also compared their predictive value to that of total plasma Aβ1-42 and Aβ1-40 levels and the total plasma Aβ1-42/Aβ1-40 ratio. METHODS The plasma Aβ1-42 and Aβ1-40 peptide assay was performed using the INNO-BIA kit (Fujirebio Europe). Free amyloid levels (defined by the amyloid fraction directly accessible to antibodies of the assay) were obtained with the undiluted plasma, whereas total amyloid levels were obtained after the dilution of plasma (1/3) with a denaturing buffer. Free and total Aβ1-42 and Aβ1-40 levels were measured at inclusion for a subgroup of participants (N = 106) with mild cognitive impairment (MCI) from the BALTAZAR study (a large-scale longitudinal multicenter cohort with a three-year follow-up). Associations between conversion and the free/total plasma Aβ1-42 and Aβ1-40 levels and Aβ1-42/Aβ1-40 ratio were analyzed using logistic and Cox Proportional Hazards models. Demographic, clinical, cognitive (MMSE, ADL and IADL), APOE, and MRI characteristics (relative hippocampal volume) were compared using non-parametric (Mann-Whitney) or parametric (Student) tests for quantitative variables and Chi-square or Fisher exact tests for qualitative variables. RESULTS The risk of conversion to dementia was lower for patients in the highest quartile of free plasma Aβ1-42/Aβ1-40 (≥ 25.8%) than those in the three lower quartiles: hazard ratio = 0.36 (95% confidence interval [0.15-0.87]), after adjustment for age, sex, education, and APOE ε4 (p-value = 0.022). This was comparable to the risk of conversion in the highest quartile of total plasma Aβ1-42/Aβ1-40: hazard ratio = 0.37 (95% confidence interval [0.16-0.89], p-value = 0.027). However, while patients in the highest quartile of total plasma Aβ1-42/Aβ1-40 showed higher MMSE scores and a higher hippocampal volume than patients in the three lowest quartiles of total plasma Aβ1-42/Aβ1-40, as well as normal CSF biomarker levels, the patients in the highest quartile of free plasma Aβ1-42/Aβ1-40 did not show any significant differences in MMSE scores, hippocampal volume, or CSF biomarker levels relative to the three lowest quartiles of free plasma Aβ1-42/Aβ1-40. CONCLUSION The free plasma Aβ1-42/Aβ1-40 ratio is associated with a risk of conversion from MCI to dementia within three years, with performance comparable to that of the total plasma Aβ1-42/Aβ1-40 ratio. Threshold levels of the free and total plasma Aβ1-42/Aβ1-40 ratio could be determined, with a 60% lower risk of conversion for patients above the threshold than those below.
Collapse
Affiliation(s)
- S Schraen-Maschke
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France.
| | - A Duhamel
- Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France
| | - J S Vidal
- Université de Paris, EA 4468 and APHP, Hôpital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Paris, France
| | - N Ramdane
- Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France
| | - L Vaudran
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France
| | - C Dussart
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France
| | - L Buée
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France
| | - B Sablonnière
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France
| | - C Delaby
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
| | - B Allinquant
- UMR-S1266, Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, Paris, France
| | - A Gabelle
- CMRR, Université de Montpellier, INM INSERM, CHU de Montpellier, Montpellier, France
| | - S Bombois
- Univ. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France
| | - S Lehmann
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
| | - O Hanon
- Université de Paris, EA 4468 and APHP, Hôpital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Paris, France.
| |
Collapse
|
4
|
Lehmann S, Schraen-Maschke S, Vidal JS, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Delaby C, Hanon O. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum. Int J Mol Sci 2023; 24:17361. [PMID: 38139190 PMCID: PMC10743700 DOI: 10.3390/ijms242417361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 12/04/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer's disease (AD). In this study, we investigated the relationship between baseline plasma concentration of Nfl and Mild Cognitive Impairment in participants who did and did not have a clinically determined diagnosis of dementia by the end of the three-year study. Additionally, we explored the connection between baseline plasma concentration of NfL and AD dementia patients, considering their demographics, clinical features, and cognitive profiles. A total of 350 participants from the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) multicenter prospective study were investigated: 161 AD dementia participants and 189 MCI participants (of which 141 had amnestic MCI and 48 non-amnestic MCI). Plasma biomarkers were measured at baseline and the progression of clinical and cognitive profiles was followed over the three years of follow-up. Baseline plasma NfL concentration increased across the Alzheimer's disease continuum with a mean NfL value of 17.1 ng/mL [SD = 6.1] in non-amnestic MCI, 20.7 ng/mL [SD = 12.0] in amnestic MCI, and 23.1 ng/mL [SD = 22.7] in AD dementia patients. Plasma NfL concentration correlated with age, body mass index (BMI), and global cognitive performance and decline, as measured by the Mini-Mental State Examination (MMSE). MMSE scores decreased in parallel with increasing plasma NfL concentration, independently of age and BMI. However, NfL concentration did not predict MCI participants' conversion to dementia within three years. Discussion: Baseline plasma NfL concentration is associated with cognitive status along the AD continuum, suggesting its usefulness as a potential informative biomarker for cognitive decline follow-up in patients.
Collapse
Affiliation(s)
- Sylvain Lehmann
- Laboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier, France;
| | - Susanna Schraen-Maschke
- Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000 Lille, France; (S.S.-M.); (S.B.)
| | - Jean-Sébastien Vidal
- Université Paris Cité, INSERM U1144, GHU APHP Centre, Hopital Broca, Memory Resource and Research Centre de Paris-Broca-Ile de France, F-75013 Paris, France; (J.-S.V.); (O.H.)
| | - Frédéric Blanc
- Université de Strasbourg, Hôpitaux Universitaires de Strasbourg, Memory Resource and Research, French National Centre for Scientific Research (CNRS), ICube Laboratory UMR7357 and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS), F-67000 Strasbourg, France;
| | - Claire Paquet
- Université Paris Cité, INSERM U1144, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, F-75010 Paris, France;
| | - Bernadette Allinquant
- Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, UMR-S 1266, F-75014 Paris, France;
| | - Stéphanie Bombois
- Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, F-59000 Lille, France; (S.S.-M.); (S.B.)
- Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, F-75013 Paris, France
| | - Audrey Gabelle
- Université de Montpellier, CHU Montpellier, Memory Research and Resources Center, Department of Neurology, Inserm INM NeuroPEPs Team, Excellence Center of Neurodegenerative Disorders, F-34000 Montpellier, France;
| | - Constance Delaby
- Laboratoire et Plateforme de Protéomique Clinique, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, 80 av Fliche, F-34295 Montpellier, France;
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, F-08041 Barcelona, Spain
| | - Olivier Hanon
- Université Paris Cité, INSERM U1144, GHU APHP Centre, Hopital Broca, Memory Resource and Research Centre de Paris-Broca-Ile de France, F-75013 Paris, France; (J.-S.V.); (O.H.)
| |
Collapse
|
5
|
Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O. Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia. Clin Chem 2023; 69:1072-1083. [PMID: 37654065 DOI: 10.1093/clinchem/hvad103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 06/06/2023] [Indexed: 09/02/2023]
Abstract
BACKGROUND Among blood biomarkers, phospho-tau181 (pTau181) is one of the most efficient in detecting Alzheimer disease across its continuum. However, transition from research to routine clinical use will require confirmation of clinical performance in prospective cohorts and evaluation of cofounding factors. METHODS Here we tested the Lumipulse assay for plasma pTau181 in mild cognitive impairment (MCI) participants from the Baltazar prospective cohort. We compared the performance of this assay to the corresponding Simoa assay for the prediction of conversion to dementia. We also evaluated the association with various routine blood parameters indicative of comorbidities. RESULTS Lumipulse and Simoa gave similar results overall, with hazard ratios for conversion to dementia of 3.48 (95% CI, 2.23-5.45) and 3.70 (95%CI, 2.39-5.87), respectively. However, the 2 tests differ somewhat in terms of the patients identified, suggesting that their use may be complementary. When combined with age, sex, and apolipoprotein E (APOE)ε4 status, areas under the curves for conversion detection were 0.736 (95% CI, 0.682-0.791) for Lumipulse and 0.733 (95% CI, 0.679-0.788) for Simoa. Plasma pTau181 was independently associated with renal dysfunction (assessed by creatinine and glomerular filtration) for both assays. Cardiovascular factors (adiponectin and cholesterol), nutritional, and inflammatory markers (total protein content, C-reactive protein) also impacted plasma pTau181 concentration, although more so with the Simoa than with the Lumipulse assay. CONCLUSIONS Plasma pTau181 measured using the fully automated Lumipulse assay performs as well as the Simoa assay for detecting conversion to dementia of MCI patients within 3 years and Lumipulse is less affected by comorbidities. This study suggests a pathway to routine noninvasive in vitro diagnosis-approved testing to contribute to the management of Alzheimer disease. CLINICALTRIALS.GOV REGISTRATION NUMBER NCT01315639.
Collapse
Affiliation(s)
- Sylvain Lehmann
- Univ Montpellier, IRMB CHU de Montpellier, INM INSERM, Montpellier, France
| | - Susanna Schraen-Maschke
- Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, University of Lille, Lille, France
| | - Jean-Sébastien Vidal
- EA 4468, APHP, Hospital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Université Paris Cité, Paris, France
| | - Constance Delaby
- Univ Montpellier, IRMB CHU de Montpellier, INM INSERM, Montpellier, France
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau-Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Frédéric Blanc
- CHRU de Strasbourg, Memory Resource and Research Centre of Strasbourg/Colmar, French National Centre for Scientific Research, ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg, Team Imagerie Multimodale Intégrative en Santé /Neurocrypto, Université de Strasbourg, Strasbourg, France
| | - Claire Paquet
- GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, Université Paris Cité, Paris, France
| | - Bernadette Allinquant
- UMR-S1266, Institute of Psychiatry and Neurosciences, Inserm, Université Paris Cité, Paris, France
| | - Stéphanie Bombois
- Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, University of Lille, Lille, France
- Assistance Publique-Hôpitaux de Paris, Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France
| | - Audrey Gabelle
- Memory Research and Resources Center, Department of Neurology, Inserm INM NeuroPEPs Team, Université de Montpellier, Montpellier, France
| | - Olivier Hanon
- EA 4468, APHP, Hospital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Université Paris Cité, Paris, France
| |
Collapse
|
6
|
Lesoil C, Bombois S, Guinebretiere O, Houot M, Bahrami M, Levy M, Genthon R, Bozon F, Jean-Marie H, Epelbaum S, Foulon P, Villain N, Dubois B. Validation study of "Santé-Cerveau", a digital tool for early cognitive changes identification. Alzheimers Res Ther 2023; 15:70. [PMID: 37013590 PMCID: PMC10068729 DOI: 10.1186/s13195-023-01204-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 03/11/2023] [Indexed: 04/05/2023]
Abstract
BACKGROUND There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool (SCD-T)) including validated questionnaires and the following neuropsychological tests: 5 Word Test (5-WT) for episodic memory, Trail Making Test (TMT) for executive functions, and a number coding test (NCT) adapted from the Digit Symbol Substitution Test for global intellectual efficiency. This study aimed to evaluate the performance of SCD-T to identify cognitive deficit and to determine its usability. METHODS Three groups were constituted including 65 elderly Controls, 64 patients with neurodegenerative diseases (NDG): 50 AD and 14 non-AD, and 20 post-COVID-19 patients. The minimum MMSE score for inclusion was 20. Association between computerized SCD-T cognitive tests and their standard equivalent was assessed using Pearson's correlation coefficients. Two algorithms (a simple clinician-guided algorithm involving the 5-WT and the NCT; and a machine learning classifier based on 8 scores from the SCD-T tests extracted from a multiple logistic regression model, and data from the SCD-T questionnaires) were evaluated. The acceptability of SCD-T was investigated through a questionnaire and scale. RESULTS AD and non-AD participants were older (mean ± standard deviation (SD): 72.61 ± 6.79 vs 69.91 ± 4.86 years old, p = 0.011) and had a lower MMSE score (Mean difference estimate ± standard error: 1.74 ± 0.14, p < 0.001) than Controls; post-COVID-19 patients were younger than Controls (mean ± SD: 45.07 ± 11.36 years old, p < 0.001). All the computerized SCD-T cognitive tests were significantly associated with their reference version. In the pooled Controls and NDG group, the correlation coefficient was 0.84 for verbal memory, -0.60 for executive functions, and 0.72 for global intellectual efficiency. The clinician-guided algorithm demonstrated 94.4% ± 3.8% sensitivity and 80.5% ± 8.7% specificity, and the machine learning classifier 96.8% ± 3.9% sensitivity and 90.7% ± 5.8% specificity. The acceptability of SCD-T was good to excellent. CONCLUSIONS We demonstrate the high accuracy of SCD-T in screening cognitive disorders and its good acceptance even in individuals with prodromal and mild dementia stages. SCD-T would be useful in primary care to faster refer subjects with significant cognitive impairment (and limit unnecessary referrals) to specialized consultation, improve the AD care pathway and the pre-screening in clinical trials.
Collapse
Affiliation(s)
- Constance Lesoil
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Stéphanie Bombois
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- INSERM U1171 - Degenerative and Vascular Cognitive Disorders, University of Lille, Lille, France
| | - Octave Guinebretiere
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Marion Houot
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
| | - Mahsa Bahrami
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Marcel Levy
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Rémy Genthon
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Frédérique Bozon
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | | | - Stéphane Epelbaum
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
| | | | - Nicolas Villain
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
- Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - Bruno Dubois
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France.
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France.
- Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.
| |
Collapse
|
7
|
Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. J Neurol Neurosurg Psychiatry 2023; 94:411-419. [PMID: 37012068 DOI: 10.1136/jnnp-2022-330540] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 12/15/2022] [Indexed: 04/05/2023]
Abstract
OBJECTIVES Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer's disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could influence its blood level. METHODS This study is ancillary to the prospective multicentre Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk cohort that enrolled participants with mild cognitive impairment (MCI) who were examined for conversion to dementia for up to 3 years. Plasma Ptau-181 was measured using the ultrasensitive Quanterix HD-X assay. RESULTS Among 476 MCI participants, 67% were amyloid positive (Aβ+) at baseline and 30% developed dementia. Plasma P-tau181 was higher in the Aβ+ population (3.9 (SD 1.4) vs 2.6 (SD 1.4) pg/mL) and in MCI that converted to dementia (3.8 (SD 1.5) vs 2.9 (SD 1.4) pg/mL). The addition of plasma P-tau181 to a logistic regression model combining age, sex, APOEε4 status and Mini Mental State Examination improved predictive performance (areas under the curve 0.691-0.744 for conversion and 0.786-0.849 for Aβ+). The Kaplan-Meier curve of conversion to dementia, according to the tertiles of plasma P-tau181, revealed a significant predictive value (Log rank p<0.0001) with an HR of 3.8 (95% CI 2.5 to 5.8). In addition, patients with plasma P-Tau(181) ≤2.32 pg/mL had a conversion rate of less than 20% over a 3-year period. Using a linear regression approach, chronic kidney disease, creatinine and estimated glomerular filtration rate were independently associated with plasma P-tau181 concentrations. CONCLUSIONS Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD. However, renal function significantly modifies its levels and may thus induce diagnostic errors if not taken into account.
Collapse
Affiliation(s)
- Sylvain Lehmann
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
| | | | - Jean-Sébastien Vidal
- Université Paris Cité, EA 4468, Hopital Broca, Geriatric department, Memory Resource and Research Centre of Paris-Broca-Ile de France, APHP, Paris, France
| | - Constance Delaby
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
- Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Frédéric Blanc
- Neuropsychology Unit and Geriatric Day Hospital, University Hospital of Strasbourg, Strasbourg, France
| | - Claire Paquet
- Université Paris Cité, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, Paris, France
| | - Bernadette Allinquant
- UMR-S 1266, Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, Paris, France
| | - Stéphanie Bombois
- Université de Lille, Inserm UMRS1172, CHU Lille, Lille, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France
| | - Audrey Gabelle
- Université de Montpellier, CHRU Montpellier, Memory Research and Resources center, department of Neurology, Inserm INM, Montpellier, France
| | - Olivier Hanon
- Université Paris Cité, EA 4468, Hopital Broca, Geriatric department, Memory Resource and Research Centre of Paris-Broca-Ile de France, APHP, Paris, France
| |
Collapse
|
8
|
Khrouf W, Saracino D, Rucheton B, Houot M, Clot F, Rinaldi D, Vitor J, Huynh M, Heng E, Schlemmer D, Pasquier F, Deramecourt V, Auriacombe S, Azuar C, Levy R, Bombois S, Boutoleau-Brétonnière C, Pariente J, Didic M, Wallon D, Fluchère F, Auvin S, Younes IB, Nadjar Y, Brice A, Dubois B, Bonnefont-Rousselot D, Le Ber I, Lamari F, Auriacombe S, Belliard S, Blanc F, Boutoleau-Brétonnière C, Brice A, Ceccaldi M, Couratier P, Didic M, Dubois B, Etcharry-Bouyx F, Formaglio M, Golfier V, Hannequin D, Lacomblez L, Lagarde J, Le Ber I, Levy R, Michel BF, Pariente J, Pasquier F, Rinaldi D, Roué-Jagot C, Sellal F, Thauvin-Robinet C, Thomas-Antérion C, Vercelletto M, Didic M, Girard N, Guedj E, Puel M, Pariente J, Berry I, Payoux P, Vercelletto M, Boutoleau-Brétonnière C, Auffray-Calvier E, Pallardy A, Pasquier F, Deramecourt V, Bombois S, Lebouvier T, Rollin A, Kuchinski G, Hannequin D, Martinaud O, Wallon D, Gerardin E, Vera P, Rinaldi D, Camuzat A, Brice A, Chupin M, Bardinet E, Kas A, Lemercier VC, Masmanian M, Oya H. Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression. Neurobiol Dis 2023; 181:106108. [PMID: 37003407 DOI: 10.1016/j.nbd.2023.106108] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 03/22/2023] [Accepted: 03/27/2023] [Indexed: 04/01/2023] Open
Abstract
GRN mutations are among the main genetic causes of frontotemporal dementia (FTD). Considering the progranulin involvement in lysosomal homeostasis, we aimed to evaluate if plasma lysosphingolipids (lysoSPL) are increased in GRN mutation carriers, and whether they might represent relevant fluid-based biomarkers in GRN-related diseases. We analyzed four lysoSPL levels in plasmas of 131 GRN carriers and 142 non-carriers, including healthy controls and patients with frontotemporal dementias (FTD) carrying a C9orf72 expansion or without any mutation. GRN carriers consisted of 102 heterozygous FTD patients (FTD-GRN), three homozygous patients with neuronal ceroid lipofuscinosis-11 (CLN-11) and 26 presymptomatic carriers (PS-GRN), the latter with longitudinal assessments. Glucosylsphingosin d18:1 (LGL1), lysosphingomyelins d18:1 and isoform 509 (LSM18:1, LSM509) and lysoglobotriaosylceramide (LGB3) were measured by electrospray ionization-tandem mass spectrometry coupled to ultraperformance liquid chromatography. Levels of LGL1, LSM18:1 and LSM509 were increased in GRN carriers compared to non-carriers (p < 0.0001). No lysoSPL increases were detected in FTD patients without GRN mutations. LGL1 and LSM18:1 progressively increased with age at sampling, and LGL1 with disease duration, in FTD-GRN. Among PS-GRN carriers, LSM18:1 and LGL1 significantly increased over 3.4-year follow-up. LGL1 levels were associated with increasing neurofilaments in presymptomatic carriers. This study evidences an age-dependent increase of β-glucocerebrosidase and acid sphingomyelinase substrates in GRN patients, with progressive changes as early as the presymptomatic phase. Among FTD patients, plasma lysoSPL appear to be uniquely elevated in GRN carriers, and thus might serve as suitable non-invasive disease-tracking biomarkers of progression, specific to the pathophysiological process. Finally, this study might add lysoSPL to the portfolio of fluid-based biomarkers, and pave the way to disease-modifying approaches based on lysosomal function rescue in GRN diseases.
Collapse
|
9
|
Tanguy D, Rametti-Lacroux A, Bouzigues A, Saracino D, Le Ber I, Godefroy V, Morandi X, Jannin P, Levy R, Batrancourt B, Migliaccio R, Azuar C, Dubois B, Lecouturier K, Araujo CM, Janvier E, Jourdain A, Rametti-Lacroux A, Coriou S, Brochard VB, Gaudebout C, Ferrand-Verdejo J, Bonnefous L, Pochan-Leva F, Jeanne L, Joulié M, Provost M, Renaud R, Hachemi S, Guillemot V, Bendetowicz D, Carle G, Socha J, Pineau F, Marin F, Liu Y, Mullot P, Mousli A, Blossier A, Visentin G, Tanguy D, Godefroy V, Sezer I, Boucly M, Cabrol-Douat B, Odobez R, Marque C, Tessereau-Barbot D, Raud A, Funkiewiez A, Chamayou C, Cognat E, Le Bozec M, Bouzigues A, Le Du V, Bombois S, Simard C, Fulcheri P, Guitton H, Peltier C, Lejeune FX, Jorgensen L, Mariani LL, Corvol JC, Valero-Cabre A, Garcin B, Volle E, Le Ber I, Migliaccio R, Levy R. Behavioural disinhibition in frontotemporal dementia investigated within an ecological framework. Cortex 2023; 160:152-166. [PMID: 36658040 DOI: 10.1016/j.cortex.2022.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 09/29/2022] [Accepted: 11/09/2022] [Indexed: 12/29/2022]
Abstract
Disinhibition is a core symptom in behavioural variant frontotemporal dementia (bvFTD) particularly affecting the daily lives of both patients and caregivers. Yet, characterisation of inhibition disorders is still unclear and management options of these disorders are limited. Questionnaires currently used to investigate behavioural disinhibition do not differentiate between several subtypes of disinhibition, encompass observation biases and lack of ecological validity. In the present work, we explored disinhibition in an original semi-ecological situation, by distinguishing three categories of disinhibition: compulsivity, impulsivity and social disinhibition. First, we measured prevalence and frequency of these disorders in 23 bvFTD patients and 24 healthy controls (HC) in order to identify the phenotypical heterogeneity of disinhibition. Then, we examined the relationships between these metrics, the neuropsychological scores and the behavioural states to propose a more comprehensive view of these neuropsychiatric manifestations. Finally, we studied the context of occurrence of these disorders by investigating environmental factors potentially promoting or reducing them. As expected, we found that patients were more compulsive, impulsive and socially disinhibited than HC. We found that 48% of patients presented compulsivity (e.g., repetitive actions), 48% impulsivity (e.g., oral production) and 100% of the patients group showed social disinhibition (e.g., disregards for rules or investigator). Compulsivity was negatively related with emotions recognition. BvFTD patients were less active if not encouraged in an activity, and their social disinhibition decreased as activity increased. Finally, impulsivity and social disinhibition decreased when patients were asked to focus on a task. Summarising, this study underlines the importance to differentiate subtypes of disinhibition as well as the setting in which they are exhibited, and points to stimulating area for non-pharmacological management.
Collapse
Affiliation(s)
- Delphine Tanguy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, Rennes, France
| | - Armelle Rametti-Lacroux
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Arabella Bouzigues
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Dario Saracino
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtriѐre, Department of Neurology, IM2A, Paris, France
| | - Isabelle Le Ber
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtriѐre, Department of Neurology, IM2A, Paris, France
| | - Valérie Godefroy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Xavier Morandi
- Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, Rennes, France
| | - Pierre Jannin
- Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, Rennes, France
| | - Richard Levy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; Univ Rennes, CHU Rennes, Inserm, LTSI - UMR 1099, Rennes, France; AP-HP, Groupe Hospitalier Pitié-Salpêtriѐre, Department of Neurology, IM2A, Paris, France
| | - Bénédicte Batrancourt
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.
| | - Raffaella Migliaccio
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, FrontLab, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtriѐre, Department of Neurology, IM2A, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Lehmann S, Schraen-Maschke S, Vidal JS, Allinquant B, Bombois S, Gabelle A, Hanon O. Plasma Aβ42/Aβ40 ratio is independent of renal function. Alzheimers Dement 2023. [PMID: 36774628 DOI: 10.1002/alz.12949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 12/17/2022] [Accepted: 12/22/2022] [Indexed: 02/13/2023]
Affiliation(s)
- Sylvain Lehmann
- LBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, Montpellier, France
| | - Susanna Schraen-Maschke
- Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France
| | - Jean-Sébastien Vidal
- Université de Paris, EA 4468, APHP, Hopital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Paris, France
| | - Bernadette Allinquant
- UMR-S1266, Université Paris Cité, Institute of Psychiatry and Neurosciences, Inserm, Paris, France
| | - Stéphanie Bombois
- Univ. Lille, Inserm, CHU Lille, UMR-S-U1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Département de Neurologie, Centre des Maladies Cognitives et Comportementales, GH Pitié-Salpêtrière, Paris, France
| | - Audrey Gabelle
- CMRR, Université de Montpellier, INM INSERM, CHU de Montpellier, Montpellier, France
| | - Olivier Hanon
- Université de Paris, EA 4468, APHP, Hopital Broca, Memory Resource and Research Centre of de Paris-Broca-Ile de France, Paris, France
| |
Collapse
|
11
|
Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Baret-Rose C, Tréluyer JM, Abdoul H, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert P, Godefroy O, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A. Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimers Dement 2022; 18:2537-2550. [PMID: 35187794 DOI: 10.1002/alz.12613] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 10/20/2021] [Accepted: 12/10/2021] [Indexed: 01/31/2023]
Abstract
INTRODUCTION Blood-based biomarkers are the next challenge for Alzheimer's disease (AD) diagnosis and prognosis. METHODS Mild cognitive impairment (MCI) participants (N = 485) of the BALTAZAR study, a large-scale longitudinal multicenter cohort, were followed-up for 3 years. A total of 165 of them converted to dementia (95% AD). Associations of conversion and plasma amyloid beta (Aβ)1-42 , Aβ1-40 , Aβ1-42 /Aβ1-40 ratio were analyzed with logistic and Cox models. RESULTS Converters to dementia had lower level of plasma Aβ1-42 (37.1 pg/mL [12.5] vs. 39.2 [11.1] , P value = .03) and lower Aβ1-42 /Aβ1-40 ratio than non-converters (0.148 [0.125] vs. 0.154 [0.076], P value = .02). MCI participants in the highest quartile of Aβ1-42 /Aβ1-40 ratio (>0.169) had a significant lower risk of conversion (hazard ratio adjusted for age, sex, education, apolipoprotein E ε4, hippocampus atrophy = 0.52 (95% confidence interval [0.31-0.86], P value = .01). DISCUSSION In this large cohort of MCI subjects we identified a threshold for plasma Aβ1-42 /Aβ1-40 ratio that may detect patients with a low risk of conversion to dementia within 3 years.
Collapse
Affiliation(s)
- Olivier Hanon
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Université de Paris, EA 4468, APHP, Hopital Broca, Paris, France
| | - Jean-Sébastien Vidal
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Université de Paris, EA 4468, APHP, Hopital Broca, Paris, France
| | - Sylvain Lehmann
- CHU Montpellier, LBPC, Inserm, Université de Montpellier, Montpellier, France
| | - Stéphanie Bombois
- CHU Lille, U1172-LilNCog, LiCEND, LabEx DISTALZ, Université de Lille, Inserm, Lille, France
| | - Bernadette Allinquant
- UMR-S 1266, Université de Paris, Institute of Psychiatric and Neurosciences, Inserm, Paris, France
| | - Christiane Baret-Rose
- UMR-S 1266, Université de Paris, Institute of Psychiatric and Neurosciences, Inserm, Paris, France
| | - Jean-Marc Tréluyer
- Clinical Research Unit, Université de Paris, APHP, Hôpital Necker, Paris, France
| | - Hendy Abdoul
- Clinical Research Unit, Université de Paris, APHP, Hôpital Necker, Paris, France
| | - Patrick Gelé
- CHU Lille, CRB/CIC1403, Université de Lille, Inserm, Lille, France
| | - Christine Delmaire
- CHU Lille, U1172-LilNCog, LiCEND, LabEx DISTALZ, Université de Lille, Inserm, Lille, France
| | - Fredéric Blanc
- CM2R, pôle de Gériatrie, Laboratoire ICube, FMTS, CNRS, équipe IMIS, Université de Strasbourg, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Jean-François Mangin
- Neurospin, CEA, CNRS, cati-neuroimaging.com, CATI Multicenter Neuroimaging Platform, Université Paris-Saclay, Gif-sur-Yvette, France
| | - Luc Buée
- CHU Lille, U1172-LilNCog, LiCEND, LabEx DISTALZ, Université de Lille, Inserm, Lille, France
| | - Jacques Touchon
- Department of Neurology, Memory Research and Resources Center of Montpellier, Inserm INM NeuroPEPs Team, Excellence Center of Neurodegenerative Disorders, Université de Montpellier, CHU Montpellier, Montpellier, France
| | - Jacques Hugon
- APHP, Groupe Hospitalier Saint Louis-Lariboisière Fernand Widal, Center of Cognitive Neurology, Université de Paris, Paris, France
| | - Bruno Vellas
- Memory Resource and Research Centre of Midi-Pyrénées, Université de Toulouse III, CHU La Grave-Casselardit, Toulouse, France
| | - Evelyne Galbrun
- Department of Gérontology 2, Sorbonne Université, APHP, Centre Hospitalier Dupuytren, Draveil, France
| | - Athanase Benetos
- Memory Resource and Research Centre of Lorraine, Université de Lorraine, CHRU de Nancy, Vandoeuvre-lès-Nancy, France
| | - Gilles Berrut
- Department of Clinical Gerontology, Memory Research Resource Center of Nantes, Université de Nantes, EA 4334 Movement-Interactions-Performance, CHU Nantes, Nantes, France
| | - Elena Paillaud
- Service de Gériatrie, Université de Paris, APHP, Hôpital Europeen Georges Pompidou, Paris, France
| | - David Wallon
- CHU de Rouen, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, CIC-CRB1404, Normandie Univ, UNIROUEN, Inserm U1245, Rouen, France
| | | | - Lisette Volpe-Gillot
- Service de Neuro-Psycho-Gériatrie, Memory Clinic, Hôpital Léopold Bellan, Paris, France
| | - Marc Paccalin
- Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Poitiers, France
| | - Philippe Robert
- Memory Research Resource Center of Nice, CoBTek lab, Université Côte d'Azur, CHU de Nice, Nice, France
| | - Olivier Godefroy
- Memory Resource and Research Centre of Amiens Picardie, CHU d'Amiens-Picardie, Amiens, France
| | - Vincent Camus
- CHRU de Tours, UMR Inserm U1253, Université François-Rabelais de Tours, Tours, France
| | - Joël Belmin
- Service de Gériatrie Ambulatoire, Sorbonne Université, APHP, Hôpitaux Universitaires Pitie-Salpêtrière-Charles Foix, Paris, France
| | - Pierre Vandel
- Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, CHU de Besançon, Memory Resource and Research Centre of Besançon Franche-Comté, Université Bourgogne Franche-Comté, Besançon, France
| | - Jean-Luc Novella
- Memory Resource and Research Centre of Champagne-Ardenne, Université de Reims Champagne-Ardenne, EA 3797, CHU de Reims, Reims, France
| | - Emmanuelle Duron
- Département de gériatrie, Équipe MOODS, Inserm 1178, Université Paris-Saclay, APHP, Hôpital Paul Brousse, Villejuif, France
| | - Anne-Sophie Rigaud
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Université de Paris, EA 4468, APHP, Hopital Broca, Paris, France
| | | | - Audrey Gabelle
- Department of Neurology, Memory Research and Resources Center of Montpellier, Inserm INM NeuroPEPs Team, Excellence Center of Neurodegenerative Disorders, Université de Montpellier, CHU Montpellier, Montpellier, France
| | | |
Collapse
|
12
|
Godefroy V, Batrancourt B, Charron S, Bouzigues A, Sezer I, Bendetowicz D, Carle G, Rametti-Lacroux A, Bombois S, Cognat E, Migliaccio R, Levy R. Disentangling Clinical Profiles of Apathy in Behavioral Variant Frontotemporal Dementia. J Alzheimers Dis 2022; 90:639-654. [PMID: 36155506 PMCID: PMC9697059 DOI: 10.3233/jad-220370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Apathy is highly frequent in behavioral variant frontotemporal dementia (bvFTD). It is presumed to involve different pathophysiological mechanisms and neuroanatomical regions. OBJECTIVE We explored the hypothesis that subgroups showing distinct profiles of apathy and distinct patterns of atrophy within frontal lobes could be disentangled in bvFTD. METHODS Using data-driven clustering applied to 20 bvFTD patients, we isolated subgroups according to their profiles on the three subscales of the Dimensional Apathy Scale (DAS). We explored their apathy profiles and atrophy patterns. Apathy profiles were characterized through both subjective measures of apathy by questionnaires and measures including objective behavioral metrics. Atrophy patterns were obtained by voxel-based morphometry, contrasting each bvFTD subgroup with healthy controls (N = 16). RESULTS By clustering based on DAS dimensions, we disentangled three subgroups of bvFTD patients, with distinct apathy profiles and atrophy patterns. One subgroup, which presented the smallest pattern of atrophy (including orbitofrontal cortex) with a right asymmetry, was characterized by high self-reported emotional and initiation apathy and by a self-initiation deficit reversible by external guidance. In other subgroups showing more diffuse bilateral atrophies extending to lateral prefrontal cortex, apathy was not reversible by external guidance and more difficulty to focus on goal-management was observed, especially in the subgroup with the largest atrophy and highest levels of executive apathy. CONCLUSION Distinct clinical profiles of apathy, corresponding to distinct anatomical subtypes of bvFTD, were identified. These findings have implications for clinicians in a perspective of precision medicine as they could contribute to personalize treatments of apathy.
Collapse
Affiliation(s)
- Valérie Godefroy
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Bénédicte Batrancourt
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Sylvain Charron
- INSERM U1266, Institut de Psychiatrie et Neurosciences de Paris, Université de Paris, Paris, France.,Department of Neuroradiology, Hôpital Sainte-Anne, Université de Paris, Paris, France
| | - Arabella Bouzigues
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Idil Sezer
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - David Bendetowicz
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.,Department of Neurology, IM2A, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Behavioural Neuropsychiatry Unit, AP-HP, Hôpital de la Salpêtrière, Paris, France
| | - Guilhem Carle
- Behavioural Neuropsychiatry Unit, AP-HP, Hôpital de la Salpêtrière, Paris, France
| | - Armelle Rametti-Lacroux
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Stéphanie Bombois
- Department of Neurology, IM2A, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Emmanuel Cognat
- UMRS 1144, INSERM, F-5010, Université de Paris, Paris, France.,Centre de Neurologie Cognitive, Hôpital Lariboisière Fernand-Widal, APHP Nord, Paris, France
| | - Raffaella Migliaccio
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.,Department of Neurology, IM2A, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Behavioural Neuropsychiatry Unit, AP-HP, Hôpital de la Salpêtrière, Paris, France
| | - Richard Levy
- Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.,Department of Neurology, IM2A, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Behavioural Neuropsychiatry Unit, AP-HP, Hôpital de la Salpêtrière, Paris, France
| |
Collapse
|
13
|
Peltier C, Lejeune FX, Jorgensen LGT, Rametti-Lacroux A, Tanguy D, Godefroy V, Bendetowicz D, Carle G, Cognat E, Bombois S, Migliaccio R, Levy R, Marin F, Batrancourt B. A temporal classification method based on behavior time series data in patients with behavioral variant of frontotemporal dementia and apathy. J Neurosci Methods 2022; 376:109625. [PMID: 35653896 DOI: 10.1016/j.jneumeth.2022.109625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 04/22/2022] [Accepted: 05/18/2022] [Indexed: 10/18/2022]
Affiliation(s)
- Caroline Peltier
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; Centre des Sciences du Goût et de l'Alimentation (CSGA), ChemoSens Platform, AgroSup Dijon, CNRS, INRAE, University of Bourgogne Franche-Comté, PROBE Research Infrastructure, Dijon, France
| | - François-Xavier Lejeune
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Lars G T Jorgensen
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Armelle Rametti-Lacroux
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Delphine Tanguy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Valérie Godefroy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - David Bendetowicz
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Guilhem Carle
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Emmanuel Cognat
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Stéphanie Bombois
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France
| | - Raffaella Migliaccio
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; AP-HP, Hôpital de la Pitié Salpêtrière, Department of Neurology, Center of excellence of neurodegenerative disease (CoEN), Institute of Memory and Alzheimer's Disease (IM2A), F-75013 Paris, France
| | - Richard Levy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France; AP-HP, Hôpital de la Pitié Salpêtrière, Department of Neurology, Center of excellence of neurodegenerative disease (CoEN), Institute of Memory and Alzheimer's Disease (IM2A), F-75013 Paris, France
| | - Frédéric Marin
- Centre of Excellence for Human and Animal Movement Biomechanics (CoEMoB), Laboratoire de BioMécanique et BioIngénierie (UMR CNRS 7338), Université de Technologie de Compiègne (UTC), Alliance Sorbonne Université, 60200 Compiègne, France
| | - Bénédicte Batrancourt
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.
| | | |
Collapse
|
14
|
Glasman P, Houot M, Migliaccio R, Bombois S, Gagliardi G, Cacciamani F, Habert MO, Dubois B, Epelbaum S. Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. Exp Gerontol 2022; 161:111715. [DOI: 10.1016/j.exger.2022.111715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 01/03/2022] [Accepted: 01/25/2022] [Indexed: 11/15/2022]
|
15
|
Delbeuck X, Pollet M, Pasquier F, Bombois S, Moroni C. The Clinical Value of the Faux Pas Test for Diagnosing Behavioral-Variant Frontotemporal Dementia. J Geriatr Psychiatry Neurol 2022; 35:62-65. [PMID: 33030088 DOI: 10.1177/0891988720964253] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE We studied the clinical value of the faux pas test to diagnose behavioral-variant frontotemporal dementia. METHODS The faux pas test was administered to patients referred to a memory clinic in a context of behavioral disturbances. The diagnosis of behavioral-variant frontotemporal dementia (n = 14) or not (n = 25) was confirmed after a 3 years follow-up. RESULTS The faux pas test displayed a high sensitivity for behavioral-variant frontotemporal dementia (.83) however its specificity was only moderate (.64). CONCLUSIONS Our results confirm that the FPT capture's specific cognitive impairments in patients with behavioral-variant frontotemporal dementia. However, some patients with psychiatric disease or other neurological diseases may also show impaired scores.
Collapse
Affiliation(s)
- Xavier Delbeuck
- Univ-Lille, INSERM UMR-S 1171, CMRR and CNRMAJ, CHU Lille, DistAlz, Lille, France
| | - Marianne Pollet
- Univ-Lille, INSERM UMR-S 1171, CMRR and CNRMAJ, CHU Lille, DistAlz, Lille, France
| | - Florence Pasquier
- Univ-Lille, INSERM UMR-S 1171, CMRR and CNRMAJ, CHU Lille, DistAlz, Lille, France
| | - Stéphanie Bombois
- Univ-Lille, INSERM UMR-S 1171, CMRR and CNRMAJ, CHU Lille, DistAlz, Lille, France
| | - Christine Moroni
- Equipe NACA, Laboratoire PSITEC, EA 4072, UFR de Psychologie, Univ-Lille, Pont de Bois, Villeneuve d'Ascq, France
| |
Collapse
|
16
|
Villain N, Dubois B, Frisoni GB, Rabinovici GD, Sabbagh MN, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert M, Nordberg AK, Blennow K, Galasko DR, Stern Y, Rowe CC, Salloway SP, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (IWG). Alzheimers Dement 2021. [DOI: 10.1002/alz.051167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Nicolas Villain
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Bruno Dubois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Sorbonne Université, AP‐HP, Hôpital de la Pitié‐Salpêtrière, Boulevard de l'hôpital Paris France
| | - Giovanni B. Frisoni
- Memory Clinic and LANVIE‐Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva Geneva Switzerland
- University of Geneva Geneva Switzerland
- IRCCS Fatebenefratelli Brescia Italy
| | - Gil D. Rabinovici
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco San Francisco CA USA
| | | | - Stefano Cappa
- IRCCS San Giovanni di Dio Fatebenefratelli Brescia Italy
- IUSS Pavia Italy
| | - Alexandre Bejanin
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Stéphanie Bombois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Univ Lille, INSERM, CHU Lille, U1171 ‐ Degenerative and Vascular Cognitive Disorders Lille France
| | - Stéphane Epelbaum
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Inria, Aramis Project‐Team, Inria‐APHP Collaboration Paris France
| | - Marc Teichmann
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Marie‐Odile Habert
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Nuclear Medicine Paris France
- Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, LIB Paris France
| | - Agneta K. Nordberg
- Center for Alzheimer Research Karolinska Institutet, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Huddinge Sweden
- Karolinska University Hospital, Theme Aging Stockholm Sweden
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal Sweden
- Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden
| | - Doug R. Galasko
- Department of Neurosciences, University of California San Diego La Jolla CA USA
| | - Yaakov Stern
- Cognitive Neuroscience Division, Department of Neurology, Columbia University New York NY USA
| | - Christopher C. Rowe
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Stephen P. Salloway
- Alpert Medical School of Brown University Providence RI USA
- Department of Psychiatry, Alpert Medical School of Brown University Providence RI USA
- Butler Hospital Providence RI USA
| | - Lon S. Schneider
- Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California Los Angeles CA USA
| | - Jeffrey L. Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas NV USA
- Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV) Las Vegas NV USA
| | - Howard H. Feldman
- Alzheimer's Disease Cooperative Study San Diego CA USA
- University of California San Diego La Jolla CA USA
- Shiley‐Marcos Alzheimer's Disease Research Center La Jolla CA USA
| |
Collapse
|
17
|
Tanguy D, Batrancourt B, Bouzigues A, Godefroy V, Bendetowicz D, Rametti‐Lacroux A, Bombois S, Cognat E, Le Ber I, Morandi X, Jannin P, Levy R, Migliaccio R. Reduction of behavioural inhibition disorders in behavioural variant frontotemporal dementia patients observed under semi‐ecological conditions. Alzheimers Dement 2021. [DOI: 10.1002/alz.051639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Delphine Tanguy
- Univ Rennes, CHU Rennes, Inserm, LTSI – UMR 1099 Rennes France
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
| | - Bénédicte Batrancourt
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
| | - Arabella Bouzigues
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
| | - Valérie Godefroy
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
| | - David Bendetowicz
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
- AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière, Department of Neurology, IM2A Paris France
| | | | - Stéphanie Bombois
- AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière, Department of Neurology, IM2A Paris France
| | - Emmanuel Cognat
- Cognitive Neurology Center, GH Saint‐Louis ‐ Lariboisière ‐ Fernand‐Widal, APHP Paris France
| | - Isabelle Le Ber
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
- AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière, Department of Neurology, IM2A Paris France
| | - Xavier Morandi
- Univ Rennes, CHU Rennes, Inserm, LTSI – UMR 1099 Rennes France
| | - Pierre Jannin
- Univ Rennes, CHU Rennes, Inserm, LTSI – UMR 1099 Rennes France
| | - Richard Levy
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
- AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière, Department of Neurology, IM2A Paris France
| | - Raffaella Migliaccio
- Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06, ICM Paris France
- AP‐HP, Groupe Hospitalier Pitié‐Salpêtrière, Department of Neurology, IM2A Paris France
| |
Collapse
|
18
|
Dubois B, Villain N, Frisoni G, Rabinovici GD, Sabbagh MN, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert M, Nordberg AK, Blennow K, Galasko DR, Stern Y, Rowe CC, Salloway SP, Schneider LS, Cummings JL, Feldman H. Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.057538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Bruno Dubois
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié‐Salpêtrière Hospital, AP‐HP Paris, France Paris France
- Brain and Spine Institute, Salpêtrière's Hospital Paris France
| | - Nicolas Villain
- Institut du Cerveau ‐ ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Giovanni Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva Geneva Switzerland
- Memory Clinic, Geneva University Hospitals Geneva Switzerland
| | - Gil D. Rabinovici
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco San Francisco CA USA
| | | | - Stefano Cappa
- IRCCS San Giovanni di Dio Fatebenefratelli Brescia Italy
- IUSS Pavia Italy
| | - Alexandre Bejanin
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Stéphanie Bombois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Stéphane Epelbaum
- APHP,Sorbonne Universités, Inserm, CNRS, Institut du Cerveau et de la Moelle epinière (ICM), Aramis Project‐Team, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié‐Salpêtrière Paris France
- Institut du Cerveau et de la Moelle Épinière (ICM) Aramis Lab, INSERM U 1127, CNRS UMR 7225 Paris France
| | - Marc Teichmann
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Marie‐Odile Habert
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Nuclear Medicine Paris France
- Centre pour l’Acquisition et le Traitement des Images (www.cati‐neuroimaging.com) Paris France
- Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, F‐75013 Paris France
| | - Agneta K. Nordberg
- Center for Alzheimer Research Karolinska Institutet, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Huddinge Sweden
- Karolinska University Hospital, Theme Aging Stockholm Sweden
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
| | - Doug R. Galasko
- Department of Neurosciences, University of California San Diego La Jolla CA USA
| | - Yaakov Stern
- Columbia University Irving Medical Center New York NY USA
| | - Christopher C. Rowe
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Stephen P. Salloway
- Department of Psychiatry, Alpert Medical School of Brown University Providence RI USA
- Butler Hospital Providence RI USA
| | - Lon S. Schneider
- Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California Los Angeles CA USA
| | - Jeffrey L. Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health and UNLV Las Vegas NV USA
- Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV) Las Vegas NV USA
| | - Howard Feldman
- Alzheimer's Disease Cooperative Study, University of California San Diego La Jolla CA USA
| |
Collapse
|
19
|
Pollet M, Skrobala E, Lopes R, Kuchcinski G, Bordier C, Rollin-Sillaire A, Bombois S, Pasquier F, Delbeuck X. A multimodal, longitudinal study of cognitive heterogeneity in early-onset Alzheimer's disease. Eur J Neurol 2021; 28:3990-3998. [PMID: 34490682 DOI: 10.1111/ene.15097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 08/19/2021] [Accepted: 09/01/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE Alzheimer's disease (AD) is a heterogeneous pathology. Young patients with AD are particularly likely to have an atypical presentation. The objectives of the present cluster analysis were to determine whether patients with early-onset AD (EOAD) had several distinct cognitive profiles and to compare the resulting clusters with regard to clinical, neuroimaging, and laboratory characteristics. METHODS We collected cognitive, behavioural, functional, neuroimaging, and laboratory data on 72 patients meeting the criteria for probable mild EOAD. The patients were first classified into clinical phenotype groups by a multidisciplinary board of clinicians. The patients' cognitive and functional decline was monitored for 24 months. A k-means clustering analysis was then used to determine clusters on the basis of the patients' neuropsychological test results. RESULTS Two distinct clusters were identified: the patients in the first cluster (C1, n = 38) had a predominant memory impairment, whereas patients in the second (C2, n = 34) did not. Dyslipidaemia and the presence of ɛ4 apolipoprotein E allele were more frequent in C1, whereas the cognitive and functional decline was faster in the patients in C2. Moreover, posterior brain abnormalities were more severe in patients in C2 than in patients in C1. CONCLUSIONS By applying a k-means clustering analysis, we identified two clusters of patients in an EOAD cohort. The clusters differed with regard to certain clinical, imaging, and laboratory characteristics. This clustering procedure might be of value for managing patients with EOAD in general and for identifying those at risk of more rapid decline in particular.
Collapse
Affiliation(s)
- Marianne Pollet
- Department of Neurology, Lille University Hospital Centre, Memory Centre, Reference Centre for Early-Onset Alzheimer Disease and Related Disorders, Lille, France
| | - Emilie Skrobala
- Lille University Hospital Centre, DISTALZ, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease, Lille, France
| | - Renaud Lopes
- University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France.,Department of Neuroradiology, Lille University Hospital Centre, Lille, France.,University of Lille, French National Centre for Scientific Research, French National Institute of Health and Medical Research, Pasteur Institute of Lille, US41-UMS 2014 - PLBS, Lille, France
| | - Grégory Kuchcinski
- Lille University Hospital Centre, DISTALZ, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease, Lille, France.,University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France.,Department of Neuroradiology, Lille University Hospital Centre, Lille, France
| | - Cécile Bordier
- University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France.,Department of Neuroradiology, Lille University Hospital Centre, Lille, France
| | - Adeline Rollin-Sillaire
- Department of Neurology, Lille University Hospital Centre, Memory Centre, Reference Centre for Early-Onset Alzheimer Disease and Related Disorders, Lille, France.,Lille University Hospital Centre, DISTALZ, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease, Lille, France.,University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Stéphanie Bombois
- Department of Neurology, Lille University Hospital Centre, Memory Centre, Reference Centre for Early-Onset Alzheimer Disease and Related Disorders, Lille, France.,University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Florence Pasquier
- Department of Neurology, Lille University Hospital Centre, Memory Centre, Reference Centre for Early-Onset Alzheimer Disease and Related Disorders, Lille, France.,Lille University Hospital Centre, DISTALZ, Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease, Lille, France.,University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Xavier Delbeuck
- Department of Neurology, Lille University Hospital Centre, Memory Centre, Reference Centre for Early-Onset Alzheimer Disease and Related Disorders, Lille, France.,University of Lille, French National Institute of Health and Medical Research U1172, Lille Neuroscience & Cognition, Degenerative and Vascular Cognitive Disorders, Lille, France
| |
Collapse
|
20
|
Delorme C, Houot M, Rosso C, Carvalho S, Nedelec T, Maatoug R, Pitron V, Gassama S, Sambin S, Bombois S, Herlin B, Ouvrard G, Bruneteau G, Hesters A, Gales AZ, Millet B, Lamari F, Lehericy S, Navarro V, Rohaut B, Demeret S, Maisonobe T, Yger M, Degos B, Mariani LL, Bouche C, Dzierzynski N, Oquendo B, Ketz F, Nguyen AH, Kas A, Lubetzki C, Delattre JY, Corvol JC. The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Commun 2021; 3:fcab135. [PMID: 34401746 PMCID: PMC8344449 DOI: 10.1093/braincomms/fcab135] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/29/2021] [Accepted: 05/05/2021] [Indexed: 12/24/2022] Open
Abstract
A variety of neuropsychiatric complications has been described in association
with COVID-19 infection. Large scale studies presenting a wider picture of these
complications and their relative frequency are lacking. The objective of our
study was to describe the spectrum of neurological and psychiatric complications
in patients with COVID-19 seen in a multidisciplinary hospital centre over 6
months. We conducted a retrospective, observational study of all patients
showing neurological or psychiatric symptoms in the context of COVID-19 seen in
the medical and university neuroscience department of Assistance Publique
Hopitaux de Paris—Sorbonne University. We collected demographic data,
comorbidities, symptoms and severity of COVID-19 infection, neurological and
psychiatric symptoms, neurological and psychiatric examination data and, when
available, results from CSF analysis, MRI, EEG and EMG. A total of 249 COVID-19
patients with a de novo neurological or psychiatric
manifestation were included in the database and 245 were included in the final
analyses. One-hundred fourteen patients (47%) were admitted to the
intensive care unit and 10 (4%) died. The most frequent neuropsychiatric
complications diagnosed were encephalopathy (43%), critical illness
polyneuropathy and myopathy (26%), isolated psychiatric disturbance
(18%) and cerebrovascular disorders (16%). No patients showed
CSF evidence of SARS-CoV-2. Encephalopathy was associated with older age and
higher risk of death. Critical illness neuromyopathy was associated with an
extended stay in the intensive care unit. The majority of these neuropsychiatric
complications could be imputed to critical illness, intensive care and systemic
inflammation, which contrasts with the paucity of more direct SARS-CoV-2-related
complications or post-infection disorders.
Collapse
Affiliation(s)
- Cécile Delorme
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Marion Houot
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Institut de la Mémoire et de la maladie d'Alzheimer, Paris 75013, France.,Centre of Excellence of Neurodegenerative Disease (CoEN), Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Charlotte Rosso
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Urgences cérébro-Vasculaires, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France.,Paris Brain Institute-ICM Stroke Network, STAR Team, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Stéphanie Carvalho
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France
| | - Thomas Nedelec
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,INRIA, Aramis Project-Team, Paris 75013, France
| | - Redwan Maatoug
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Service de Psychiatrie adulte, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Victor Pitron
- Service de Psychiatrie adulte, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France.,Institut Jean-Nicod, UMR 8129, ENS/EHESS/CNRS, IEC, PSL Research University, Paris 75005, France
| | - Salimata Gassama
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Sara Sambin
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Stéphanie Bombois
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Institut de la Mémoire et de la maladie d'Alzheimer, Paris 75013, France
| | - Bastien Herlin
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Unité d'épileptologie, Paris 75013, France.,Département de Médecine Physique et de réadaptation, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié Salpêtrière Hospital, Paris 75013, France
| | - Gaëlle Ouvrard
- Service de Neuro-orthopédie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Rothschild Hospital, Paris 75012, France
| | - Gaëlle Bruneteau
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France.,Centre de Recherche en Myologie, UMRS974, Association Institut de Myologie, Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Paris 75013, France
| | - Adèle Hesters
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Ana Zenovia Gales
- Service des Pathologies du sommeil, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Bruno Millet
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Service de Psychiatrie adulte, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Foudil Lamari
- Département de Biochimie Métabolique, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Stéphane Lehericy
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neuroradiologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Vincent Navarro
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Unité d'épileptologie, Paris 75013, France.,Département de Neurophysiologie Clinique, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Benjamin Rohaut
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Sophie Demeret
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Thierry Maisonobe
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France.,Département de Neurophysiologie Clinique, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Marion Yger
- Unité de Soins intentifs neurovasculaires, Assistance Publique Hôpitaux de Paris, Sorbonne Université Saint-Antoine Hospital, Paris 75012, France
| | - Bertrand Degos
- Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Avicenne Hospital, Bobigny 93000, France
| | - Louise-Laure Mariani
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Christophe Bouche
- Service de Psychiatrie adulte, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Nathalie Dzierzynski
- Département de Psychiatrie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Tenon Hospital, Paris 75020, France
| | - Bruno Oquendo
- Service de Gériatrie à orientation neurologique, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Charles Foix Hospital, Paris 94200, France
| | - Flora Ketz
- Service de Gériatrie polyvalente, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Charles Foix Hospital, Paris 94200, France
| | - An-Hung Nguyen
- Service d'Addictologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière, Paris 75013, France
| | - Aurélie Kas
- Service de Médecine Nucléaire et LIB, INSERM U1146, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié- Salpêtrière Hospital, Paris 75013, France
| | - Catherine Lubetzki
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | - Jean-Yves Delattre
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France
| | - Jean-Christophe Corvol
- CNRS UMR 7225, Sorbonne Université, Paris Brain Institute-ICM, Inserm U1127, Paris 75013, France.,Département de Neurologie, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Pitié-Salpêtrière Hospital, Paris 75013, France
| | | |
Collapse
|
21
|
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol 2021; 20:484-496. [PMID: 33933186 PMCID: PMC8339877 DOI: 10.1016/s1474-4422(21)00066-1] [Citation(s) in RCA: 332] [Impact Index Per Article: 110.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 01/21/2021] [Accepted: 02/18/2021] [Indexed: 12/13/2022]
Abstract
In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease.
Collapse
Affiliation(s)
- Bruno Dubois
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France.
| | - Nicolas Villain
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Giovanni B Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, University Hospital of Geneva, Geneva, Switzerland; Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy
| | - Gil D Rabinovici
- Memory and Aging Center, Department of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
| | - Marwan Sabbagh
- Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
| | - Stefano Cappa
- University School for Advanced Studies, Pavia, Italy; RCCS Mondino Foundation, Pavia, Italy
| | - Alexandre Bejanin
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Stéphanie Bombois
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; INSERM, CHU Lille, U1171 - Degenerative and vascular cognitive disorders, University of Lille, Lille, France
| | - Stéphane Epelbaum
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Inria ARAMIS project team, Inria-APHP collaboratio, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Marc Teichmann
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France
| | - Marie-Odile Habert
- AP-HP Department of Nuclear Medicine, Sorbonne University, Paris, France; CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Agneta Nordberg
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden; Theme Aging, The Aging Brain, Karolinska University Hospital, Stockholm, Sweden
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Douglas Galasko
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
| | - Yaakov Stern
- Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Stephen Salloway
- Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital, Providence, RI, USA
| | - Lon S Schneider
- Keck School of Medicine of the University of Southern California, Los Angeles, USA
| | - Jeffrey L Cummings
- Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
| | - Howard H Feldman
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; Shiley-Marcos Alzheimer's Disease Research Center, University of California San Diego, La Jolla, CA, USA; Alzheimer Disease Cooperative Study, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|
22
|
Godefroy V, Tanguy D, Bouzigues A, Sezer I, Ferrand‐Verdejo J, Azuar C, Bendetowicz D, Carle G, Rametti‐Lacroux A, Bombois S, Cognat E, Jannin P, Morandi X, Ber IL, Levy R, Batrancourt B, Migliaccio R. Frontotemporal dementia subtypes based on behavioral inhibition deficits. Alzheimers Dement (Amst) 2021; 13:e12178. [PMID: 33851004 PMCID: PMC8022767 DOI: 10.1002/dad2.12178] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 02/16/2021] [Accepted: 02/18/2021] [Indexed: 01/19/2023]
Abstract
INTRODUCTION We aimed to investigate phenotypic heterogeneity in the behavioral variant of frontotemporal dementia (bvFTD) through assessment of inhibition deficits. METHODS We assessed occurrences of 16 behavioral inhibition deficits from video recordings of 15 bvFTD patients (early stage) and 15 healthy controls (HC) in an ecological setting. We extracted dimensions of inhibition deficit and analyzed their correlations with cognitive and clinical measures. Using these dimensions, we isolated patient clusters whose atrophy patterns were explored. RESULTS After identifying two patterns of inhibition deficit (compulsive automatic behaviors and socially unconventional behaviors), we isolated three behavioral clusters with distinct atrophy patterns. BvFTD-G0 (N = 3), an outlier group, showed severe behavioral disturbances and more severe ventromedial prefrontal cortex/orbitofrontal cortex atrophy. Compared to bvFTD-G1 (N = 6), bvFTD-G2 (N = 6) presented higher anxiety and depression along with less diffuse atrophy especially in midline regions. DISCUSSION Identifying clinico-anatomical profiles through behavior observation could help to stratify bvFTD patients for adapted treatments.
Collapse
Affiliation(s)
| | - Delphine Tanguy
- Paris Brain InstituteSorbonne UniversitésParisFrance
- CHU RennesUniversité RennesRennesFrance
| | | | - Idil Sezer
- Paris Brain InstituteSorbonne UniversitésParisFrance
| | | | - Carole Azuar
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
| | - David Bendetowicz
- Paris Brain InstituteSorbonne UniversitésParisFrance
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
- Behavioural Neuropsychiatry UnitHôpital de la SalpêtrièreParisFrance
| | - Guilhem Carle
- Behavioural Neuropsychiatry UnitHôpital de la SalpêtrièreParisFrance
| | | | - Stéphanie Bombois
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
| | - Emmanuel Cognat
- Université de ParisParisFrance
- Centre de Neurologie CognitiveHôpital Lariboisière Fernand‐WidalParisFrance
| | | | | | - Isabelle Le Ber
- Paris Brain InstituteSorbonne UniversitésParisFrance
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
| | - Richard Levy
- Paris Brain InstituteSorbonne UniversitésParisFrance
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
- Behavioural Neuropsychiatry UnitHôpital de la SalpêtrièreParisFrance
| | | | - Raffaella Migliaccio
- Paris Brain InstituteSorbonne UniversitésParisFrance
- Department of NeurologyGroupe Hospitalier Pitié‐SalpêtrièreParisFrance
- Behavioural Neuropsychiatry UnitHôpital de la SalpêtrièreParisFrance
| |
Collapse
|
23
|
Dujardin K, Duhem S, Guerouaou N, Djelad S, Drumez E, Duhamel A, Bombois S, Nasreddine Z, Bordet R, Deplanque D. Validation in French of the Montreal Cognitive Assessment 5-Minute, a brief cognitive screening test for phone administration. Rev Neurol (Paris) 2021; 177:972-979. [PMID: 33478740 DOI: 10.1016/j.neurol.2020.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 08/24/2020] [Accepted: 09/10/2020] [Indexed: 10/22/2022]
Abstract
BACKGROUND The prevalence of cognitive impairment and dementia is high and steadily increasing. Early detection of cognitive decline is crucial since some interventions can reduce the risk of progression to dementia. However, there is a lack of manageable scales for assessing cognitive functions outside specialized consultations. Recently, the MoCA-5min, a short version of the Montreal Cognitive assessment (MoCA), phone-administered, was validated for screening for vascular cognitive impairment. The aim of the present study was to validate the MoCA-5min in French in diverse clinical populations. METHODS The Cantonese version of the MoCA-5min was adapted for French language. Healthy volunteers and patients with possible or established cognitive impairment (Alzheimer's disease or related disorders, Parkinson's disease, Huntington's disease, type-2 diabetes) participated in the study. The original MoCA and the MoCA-5min were administered, by phone, with a 30-day interval. Alternate forms were used to reduce learning effects. RESULTS The scores of the original MoCA and MoCA-5min correlated significantly (Spearman rho=0.751, P<0.0001, 95% confidence interval 0.657 to 0.819). Internal consistency was good (Cronbach alpha=0.795). The area under the ROC curve was 0.870 and the optimal cut-off value for separating patients with and without cognitive impairment with the MoCA-5min was≤27 with 87.32% sensitivity and 76.09% specificity. Interrater and test-retest reliability were adequate. CONCLUSION This study demonstrates that the French version of the MoCA-5min is a valid and reliable scale for detecting cognitive impairment in different clinical populations. It is administrable by phone and thus suitable for remote assessment as well as for large-scale screening and epidemiological studies.
Collapse
Affiliation(s)
- K Dujardin
- Inserm, Lille Neurosciences and Cognition, CHU de Lille, University Lille, 59000 Lille, France; Neurology and Movement Disorders, Lille University Medical Center, Lille, France.
| | - S Duhem
- Clinical Investigation Center, Lille University Medical Center, Lille, France
| | - N Guerouaou
- Clinical Investigation Center, Lille University Medical Center, Lille, France
| | - S Djelad
- Neurology and Movement Disorders, Lille University Medical Center, Lille, France
| | - E Drumez
- EA 2694 - METRICS : évaluation des technologies de santé et des pratiques médicales, CHU de Lille, University Lille, Lille, France
| | - A Duhamel
- EA 2694 - METRICS : évaluation des technologies de santé et des pratiques médicales, CHU de Lille, University Lille, Lille, France
| | - S Bombois
- Inserm, Lille Neurosciences and Cognition, CHU de Lille, University Lille, 59000 Lille, France
| | | | - R Bordet
- Inserm, Lille Neurosciences and Cognition, CHU de Lille, University Lille, 59000 Lille, France
| | - D Deplanque
- Inserm, Lille Neurosciences and Cognition, CHU de Lille, University Lille, 59000 Lille, France
| |
Collapse
|
24
|
Kas A, Soret M, Pyatigoskaya N, Habert MO, Hesters A, Le Guennec L, Paccoud O, Bombois S, Delorme C. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging 2021; 48:2543-2557. [PMID: 33452633 PMCID: PMC7810428 DOI: 10.1007/s00259-020-05178-y] [Citation(s) in RCA: 80] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 12/22/2020] [Indexed: 11/16/2022]
Abstract
Purpose Little is known about the neuronal substrates of neuropsychiatric symptoms associated with COVID-19 and their evolution during the course of the disease. We aimed at describing the longitudinal brain metabolic pattern in COVID-19-related encephalopathy using 18F-FDG-PET/CT. Methods Seven patients with variable clinical presentations of COVID-19-related encephalopathy were explored thrice with brain 18F-FDG-PET/CT, once in the acute phase, 1 month later and 6 months after COVID-19 onset. PET images were analysed with voxel-wise and regions-of-interest approaches in comparison with 32 healthy controls. Results Patients’ neurological manifestations during acute encephalopathy were heterogeneous. However, all of them presented with predominant cognitive and behavioural frontal disorders. SARS-CoV-2 RT-PCR in the CSF was negative for all patients. MRI revealed no specific abnormalities for most of the subjects. All patients had a consistent pattern of hypometabolism in a widespread cerebral network including the frontal cortex, anterior cingulate, insula and caudate nucleus. Six months after COVID-19 onset, the majority of patients clinically had improved but cognitive and emotional disorders of varying severity remained with attention/executive disabilities and anxio-depressive symptoms, and lasting prefrontal, insular and subcortical 18F-FDG-PET/CT abnormalities. Conclusion The implication of this widespread network could be the neural substrate of clinical features observed in patients with COVID-19, such as frontal lobe syndrome, emotional disturbances and deregulation of respiratory failure perception. This study suggests that this network remains mildly to severely impaired 6 months after disease onset.
Collapse
Affiliation(s)
- Aurélie Kas
- Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Médecine Nucléaire and LIB, INSERM U1146, 75013, Paris, France.
| | - Marine Soret
- Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Médecine Nucléaire and LIB, INSERM U1146, 75013, Paris, France
| | - Nadya Pyatigoskaya
- Département de Neuroradiologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, 75013, Paris, France
| | - Marie-Odile Habert
- Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Médecine Nucléaire and LIB, INSERM U1146, 75013, Paris, France
| | - Adèle Hesters
- Département de Neurologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, 75013, Paris, France
| | - Loic Le Guennec
- Département de Neurologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, 75013, Paris, France
| | - Olivier Paccoud
- Service de Maladies infectieuses et Tropicales, Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, 75013, Paris, France
| | - Stéphanie Bombois
- Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Institut de la Mémoire et de la Maladie d'Alzheimer, 75013, Paris, France
| | - Cécile Delorme
- Département de Neurologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, 75013, Paris, France
| | | |
Collapse
|
25
|
Leroy M, Bertoux M, Skrobala E, Mode E, Adnet-Bonte C, Le Ber I, Bombois S, Cassagnaud P, Chen Y, Deramecourt V, Lebert F, Mackowiak MA, Sillaire AR, Wathelet M, Pasquier F, Lebouvier T. Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alzheimers Res Ther 2021; 13:19. [PMID: 33419472 PMCID: PMC7796569 DOI: 10.1186/s13195-020-00753-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 12/16/2020] [Indexed: 12/11/2022]
Abstract
Background Due to heterogeneous clinical presentation, difficult differential diagnosis with Alzheimer’s disease (AD) and psychiatric disorders, and evolving clinical criteria, the epidemiology and natural history of frontotemporal lobar degeneration (FTD) remain elusive. In order to better characterize FTD patients, we relied on the database of a regional memory clinic network with standardized diagnostic procedures and chose AD patients as a comparator. Methods Patients that were first referred to our network between January 2010 and December 2016 and whose last clinical diagnosis was degenerative or vascular dementia were included. Comparisons were conducted between FTD and AD as well as between the different FTD syndromes, divided into language variants (lvFTD), behavioral variant (bvFTD), and FTD with primarily motor symptoms (mFTD). Cognitive progression was estimated with the yearly decline in Mini Mental State Examination (MMSE). Results Among the patients that were referred to our network in the 6-year time span, 690 were ultimately diagnosed with FTD and 18,831 with AD. Patients with FTD syndromes represented 2.6% of all-cause dementias. The age-standardized incidence was 2.90 per 100,000 person-year and incidence peaked between 75 and 79 years. Compared to AD, patients with FTD syndromes had a longer referral delay and delay to diagnosis. Patients with FTD syndromes had a higher MMSE score than AD at first referral while their progression was similar. mFTD patients had the shortest survival while survival in bvFTD, lvFTD, and AD did not significantly differ. FTD patients, especially those with the behavioral variant, received more antidepressants, anxiolytics, and antipsychotics than AD patients. Conclusions FTD syndromes differ with AD in characteristics at baseline, progression rate, and treatment. Despite a broad use of the new diagnostic criteria in an organized memory clinic network, FTD syndromes are longer to diagnose and account for a low proportion of dementia cases, suggesting persistent underdiagnosis. Congruent with recent publications, the late peak of incidence warns against considering FTD as being exclusively a young-onset dementia.
Collapse
Affiliation(s)
- Mélanie Leroy
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Maxime Bertoux
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | | | - Elisa Mode
- Univ. Lille, Inserm, CHU Lille, F-59000, Lille, France
| | - Catherine Adnet-Bonte
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Isabelle Le Ber
- Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.,Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
| | - Stéphanie Bombois
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Pascaline Cassagnaud
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Yaohua Chen
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Vincent Deramecourt
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Florence Lebert
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Marie Anne Mackowiak
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Adeline Rollin Sillaire
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | | | - Florence Pasquier
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France
| | - Thibaud Lebouvier
- Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, CNRMAJ, LiCEND, DistAlz, F-59000, Lille, France.
| | | |
Collapse
|
26
|
Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, Boullet A, Doukhi D, Le Guennec L, Godefroy N, Maatoug R, Fossati P, Millet B, Navarro V, Bruneteau G, Demeret S, Pourcher V. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol 2020; 27:2651-2657. [PMID: 32881133 PMCID: PMC7461074 DOI: 10.1111/ene.14478] [Citation(s) in RCA: 93] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Accepted: 08/11/2020] [Indexed: 12/27/2022]
Abstract
Aim The aim of this paper is to describe the clinical features of COVID‐19‐related encephalopathy and their metabolic correlates using brain 2‐desoxy‐2‐fluoro‐D‐glucose (FDG)‐positron‐emission tomography (PET)/computed tomography (CT) imaging. Background and purpose A variety of neurological manifestations have been reported in association with COVID‐19. COVID‐19‐related encephalopathy has seldom been reported and studied. Methods We report four cases of COVID‐19‐related encephalopathy. The diagnosis was made in patients with confirmed COVID‐19 who presented with new‐onset cognitive disturbances, central focal neurological signs, or seizures. All patients underwent cognitive screening, brain magnetic resonance imaging (MRI), lumbar puncture, and brain 2‐desoxy‐2‐fluoro‐D‐glucose (FDG)‐positron‐emission tomography (PET)/computed tomography (CT) (FDG‐PET/CT). Results The four patients were aged 60 years or older, and presented with various degrees of cognitive impairment, with predominant frontal lobe impairment. Two patients presented with cerebellar syndrome, one patient had myoclonus, one had psychiatric manifestations, and one had status epilepticus. The delay between first COVID‐19 symptoms and onset of neurological symptoms was between 0 and 12 days. None of the patients had MRI features of encephalitis nor significant cerebrospinal fluid (CSF) abnormalities. SARS‐CoV‐2 RT‐PCR in the CSF was negative for all patients. All patients presented with a consistent brain FDG‐PET/CT pattern of abnormalities, namely frontal hypometabolism and cerebellar hypermetabolism. All patients improved after immunotherapy. Conclusions Despite varied clinical presentations, all patients presented with a consistent FDG‐PET pattern, which may reflect an immune mechanism.
Collapse
Affiliation(s)
- C Delorme
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - O Paccoud
- Department of Infectious and Tropical diseases, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - A Kas
- Nuclear Medicine and LIB Department, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, INSERM U1146, Paris, France
| | - A Hesters
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - S Bombois
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - P Shambrook
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - A Boullet
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - D Doukhi
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - L Le Guennec
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - N Godefroy
- Department of Infectious and Tropical diseases, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - R Maatoug
- Department of adult Psychiatry, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - P Fossati
- Department of adult Psychiatry, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - B Millet
- Department of adult Psychiatry, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - V Navarro
- Department of Neurophysiology, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France
| | - G Bruneteau
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - S Demeret
- Department of Neurology, Sorbonne University, Assistance Publique des Hôpitaux de Paris (AP-HP), University Hospitals - Pitié-Salpêtrière Charles Foix, Paris, France
| | - V Pourcher
- Department of Infectious and Tropical diseases, Sorbonne University, AP-HP, University Hospitals Pitié-Salpêtrière Charles Foix, Paris, France.,Pierre Louis Institute of Epidemiology and Public Health, Sorbonne University, INSERM 1136, Paris, France
| | | |
Collapse
|
27
|
Dubois B, Bombois S, Villain N, Teichmann M, Epelbaum S, Migliaccio R, Genthon R, Verrat B, Lesoil C, Levy M, Le Ber I, Levy R. [Toward a preventive management Alzheimer's disease]. Bull Acad Natl Med 2020; 204:583-588. [PMID: 32322104 PMCID: PMC7172758 DOI: 10.1016/j.banm.2020.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 04/10/2020] [Indexed: 11/03/2022]
Abstract
Les démences et la maladie d’Alzheimer (MA), en particulier, vont devenir de plus en plus un enjeu de santé publique. Trois données importantes peuvent cependant modifier le poids de ces pathologies : (1) de simples mesures d’hygiène de vie (contrôle de facteurs de risque vasculaire, activité physique et stimulation cognitive) instaurées chez les jeunes adultes ont un impact sur un déclin cognitif ultérieur ; (2) chez des sujets âgés à risque, ces mêmes dispositions retardent l’entrée dans la maladie et (3) enfin et pour la première fois, un anticorps anti-amyloïde aurait montré un effet significatif sur l’évolution de la MA chez des patients au stade débutant. Il ressort de ces travaux qu’il faut se préparer à reconsidérer la stratégie de prise en charge des troubles cognitifs, qu’ils soient mineurs ou majeurs, et de la MA en particulier. L’entrée des patients dans le parcours de soins reste aujourd’hui trop tardive. La solution est d’agir plus précocement, voire de façon préventive. Il faut développer une offre de soins adaptée à cette situation nouvelle afin d’agir sur la maladie le plus tôt possible, fondée sur : 1) des algorithmes prédictifs pour déterminer chez les sujets sans symptômes spécifiques ceux qui seront à risque de développer une pathologie dégénérative; ces algorithmes devront être mis au point à partir de données démographiques, familiales, cognitives, génomiques et biologiques, comme celles recueillies dans le projet « Santé-Cerveau » développé en partenariat avec l’ARS et les médecins généralistes ; 2) le renforcement des activités de prévention dans les 450 centres mémoire de proximité disponibles en France et les 26 CM2R et 3) la transformation de quelques-uns de ces centres experts en « cliniques de prévention de la démence » pour tester les mesures de prévention, initier des programmes d’éducation thérapeutique multidomaine et les valider, communiquer sur le risque, répondre à la demande de sujets inquiets et déterminer, chez ceux-ci, à l’aide des algorithmes, le niveau de risque qu’ils ont de déclarer une MA dans les mois et années qui viennent, en tenant compte de la compétition entre les risques. On peut ainsi se préparer à faire bénéficier précocement les uns et les autres des traitements pharmacologiques susceptibles d’exister.
Collapse
Affiliation(s)
- B Dubois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « maladie Alzheimer Jeune ».,Centre national de référence « démences rares et précoces »
| | - S Bombois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - N Villain
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Sorbonne-Université, Paris, France
| | - M Teichmann
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - S Epelbaum
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - R Migliaccio
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France
| | - R Genthon
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - B Verrat
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - C Lesoil
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - M Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - I Le Ber
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - R Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « démences rares et précoces »
| |
Collapse
|
28
|
Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, Bae HJ, Lim JS, Köhler S, Douven E, Staals J, Chen C, Xu X, Chong EJ, Akinyemi RO, Kalaria RN, Ogunniyi A, Barbay M, Roussel M, Lee BC, Srikanth VK, Moran C, Kandiah N, Chander RJ, Sabayan B, Jukema JW, Melkas S, Erkinjuntti T, Brodaty H, Bordet R, Bombois S, Hénon H, Lipnicki DM, Kochan NA, Sachdev PS. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology 2019; 93:e2257-e2271. [PMID: 31712368 PMCID: PMC6937495 DOI: 10.1212/wnl.0000000000008612] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2018] [Accepted: 07/26/2019] [Indexed: 12/16/2022] Open
Abstract
Objective To address the variability in prevalence estimates and inconsistencies in potential risk factors for poststroke cognitive impairment (PSCI) using a standardized approach and individual participant data (IPD) from international cohorts in the Stroke and Cognition Consortium (STROKOG) consortium. Methods We harmonized data from 13 studies based in 8 countries. Neuropsychological test scores 2 to 6 months after stroke or TIA and appropriate normative data were used to calculate standardized cognitive domain scores. Domain-specific impairment was based on percentile cutoffs from normative groups, and associations between domain scores and risk factors were examined with 1-stage IPD meta-analysis. Results In a combined sample of 3,146 participants admitted to hospital for stroke (97%) or TIA (3%), 44% were impaired in global cognition and 30% to 35% were impaired in individual domains 2 to 6 months after the index event. Diabetes mellitus and a history of stroke were strongly associated with poorer cognitive function after covariate adjustments; hypertension, smoking, and atrial fibrillation had weaker domain-specific associations. While there were no significant differences in domain impairment among ethnoracial groups, some interethnic differences were found in the effects of risk factors on cognition. Conclusions This study confirms the high prevalence of PSCI in diverse populations, highlights common risk factors, in particular diabetes mellitus, and points to ethnoracial differences that warrant attention in the development of prevention strategies.
Collapse
Affiliation(s)
- Jessica W Lo
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - John D Crawford
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - David W Desmond
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Olivier Godefroy
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Hanna Jokinen
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Simin Mahinrad
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Hee-Joon Bae
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Jae-Sung Lim
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Sebastian Köhler
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Elles Douven
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Julie Staals
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Christopher Chen
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Xin Xu
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Eddie J Chong
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Rufus O Akinyemi
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Rajesh N Kalaria
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Adesola Ogunniyi
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Mélanie Barbay
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Martine Roussel
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Byung-Chul Lee
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Velandai K Srikanth
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Christopher Moran
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Nagaendran Kandiah
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Russell J Chander
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Behnam Sabayan
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - J Wouter Jukema
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Susanna Melkas
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Timo Erkinjuntti
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Henry Brodaty
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Régis Bordet
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Stéphanie Bombois
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Hilde Hénon
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Darren M Lipnicki
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Nicole A Kochan
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France
| | - Perminder S Sachdev
- From the Centre for Healthy Brain Ageing (J.W.L., J.D.C., R.J.C., H.B., D.M.L., N.A.K., P.S.S.), University of New South Wales, Sydney, Australia; Department of Neurology and Laboratory of Functional Neurosciences (O.G., M.B., M.R.), University Hospital of Amiens, France; Clinical Neurosciences (H.J., S.M., T.E.), Neurology, University of Helsinki and Helsinki University Hospital, Finland; Department of Internal Medicine (S.M.), Gerontology and Geriatrics Section, and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Department of Neurology (S.M., B.S.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.-J.B.), Seoul National University School of Medicine, Seoul National University Bundang Hospital, Seongnam; Department of Neurology (J.-S.L., B.-C.L.), Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Department of Psychiatry and Neuropsychology (S.K., E.D.), School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University; Department of Neurology (J.S.), Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands; Memory Aging and Cognition Centre (C.C., X.X., E.J.C.), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore; Centre for Population Health Sciences (X.X.), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Neuroscience and Ageing Research Unit (R.O.A., A.O.), Institute for Advanced Medical Research and Training, and Department of Medicine (R.O.A.), College of Medicine, University of Ibadan, Nigeria; Institute of Neuroscience (R.N.K.), Newcastle University, Newcastle Upon Tyne, UK; Peninsula Clinical School (V.K.S., C.M.), Central Clinical School, Monash University; Department of Aged Care (C.M.), Alfred Health, Melbourne, Australia; National Neuroscience Institute (N.K., R.J.C.); Duke-NUS Medical School (N.K.), Singapore; Dementia Collaborative Research Centre (H.B., P.S.S.), University of New South Wales, Sydney, Australia; and University of Lille (R.B., S.B., H.H.), Inserm, CHU Lille, U1171-Degenerative & Vascular Cognitive Disorders, France.
| | | |
Collapse
|
29
|
Betrouni N, Yasmina M, Bombois S, Pétrault M, Dondaine T, Lachaud C, Laloux C, Mendyk AM, Henon H, Bordet R. Texture Features of Magnetic Resonance Images: an Early Marker of Post-stroke Cognitive Impairment. Transl Stroke Res 2019; 11:643-652. [PMID: 31677092 DOI: 10.1007/s12975-019-00746-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 10/08/2019] [Accepted: 10/09/2019] [Indexed: 11/26/2022]
Abstract
Stroke is frequently associated with delayed, long-term cognitive impairment (CI) and dementia. Recent research has focused on identifying early predictive markers of CI occurrence. We carried out a texture analysis of magnetic resonance (MR) images to identify predictive markers of CI occurrence based on a combination of preclinical and clinical data. Seventy-two-hour post-stroke T1W MR images of 160 consecutive patients were examined, including 75 patients with confirmed CI at the 6-month post-stroke neuropsychological examination. Texture features were measured in the hippocampus and entorhinal cortex and compared between patients with CI and those without. A correlation study determined their association with MoCA and MMSE clinical scores. Significant features were then combined with the classical prognostic factors, age and gender, to build a machine learning algorithm as a predictive model for CI occurrence. A middle cerebral artery transient occlusion model was used. Texture features were compared in the hippocampus of sham and lesioned rats and were correlated with histologically assessed neural loss. In clinical studies, two texture features, kurtosis and inverse difference moment, differed significantly between patients with and without CI and were significantly correlated with MoCA and MMSE scores. The prediction model had an accuracy of 88 ± 3%. The preclinical model revealed a significant correlation between texture features and neural density in the hippocampus contralateral to the ischemic area. These preliminary results suggest that texture features of MR images are representative of neural alteration and could be a part of a screening strategy for the early prediction of post-stroke CI.
Collapse
Affiliation(s)
- Nacim Betrouni
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France.
| | - Moussaoui Yasmina
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Stéphanie Bombois
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Maud Pétrault
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Thibaut Dondaine
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Cédrick Lachaud
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Charlotte Laloux
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Anne-Marie Mendyk
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Hilde Henon
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| | - Régis Bordet
- Laboratoire de Pharmacologie, Faculté de Médecine, University of Lille, INSERM, CHU Lille, U1171, Degenerative & Vascular Cognitive Disorders, 1, Place de Verdun, 59000, Lille, France
| |
Collapse
|
30
|
Leturcq-Jacquemont C, Skrobala E, Hanon O, Vidal JS, Audrey G, Bombois S, Delbeuck X. Dissociation de performances entre mémoire épisodique verbale et non verbale dans le trouble cognitif léger. Rev Neurol (Paris) 2019. [DOI: 10.1016/j.neurol.2019.01.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Delbeuck X, Davion JB, Bombois S, Defebvre L, Pasquier F, Kuchcinski G, Tard C. Caractérisation neuropsychologique et en imagerie par résonnance magnétique cérébrale de patients présentant une dystrophie myotonique de type I. Rev Neurol (Paris) 2019. [DOI: 10.1016/j.neurol.2019.01.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Bombois S, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J. Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß 1-42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Front Aging Neurosci 2019; 11:11. [PMID: 30837862 PMCID: PMC6390179 DOI: 10.3389/fnagi.2019.00011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 01/11/2019] [Indexed: 11/13/2022] Open
Abstract
[This corrects the article DOI: 10.3389/fnagi.2018.00297.].
Collapse
Affiliation(s)
- Emmanuelle Duron
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France.,APHP, Hôpital Paul Brousse, Service de Gériatrie du Dr Karoubi, Villejuif, France.,Université Paris-Sud 11, Centre de Recherche en Épidemiologie et Santé des Population-Depression et Antidépresseurs, INSERM UMR-1178, Le Kremlin-Bicêtre, France
| | - Jean-Sébastien Vidal
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Dominique Grousselle
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France
| | - Audrey Gabelle
- Memory Research and Resources Center, Gui de Chauliac Hospital, University of Montpellier, Montpellier, France
| | - Sylvain Lehmann
- Laboratoire de Biochimie Protéomique Clinique, CHU Montpellier, University of Montpellier, INSERM, Montpellier, France
| | - Florence Pasquier
- University of Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France
| | - Stéphanie Bombois
- University of Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France
| | - Luc Buée
- Univ Lille, Inserm, UMRS 1172, LabEx DISTALZ, Lille, France
| | - Bernadette Allinquant
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France
| | - Susanna Schraen-Maschke
- Univ Lille, Inserm, UMRS 1172, LabEx DISTALZ, Lille, France.,UF de Neurobiologie, Centre Biologie Pathologie du CHU-Lille, Lille, France
| | - Christiane Baret
- UF de Neurobiologie, Centre Biologie Pathologie du CHU-Lille, Lille, France
| | - Anne-Sophie Rigaud
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Hanon
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jacques Epelbaum
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France.,MECADEV UMR 7179 CNRS, Muséum National d'Histoire Naturelle, Paris, France
| |
Collapse
|
33
|
Fournier C, Barbier M, Camuzat A, Anquetil V, Lattante S, Clot F, Cazeneuve C, Rinaldi D, Couratier P, Deramecourt V, Sabatelli M, Belliard S, Vercelletto M, Forlani S, Jornea L, Leguern E, Brice A, Le Ber I, Brice A, Auriacombe S, Belliard S, Blanc F, Bouteleau-Bretonnière C, Ceccaldi M, Couratier P, Didic M, Dubois B, Duyckaerts C, Etcharry-Bouix F, Golfier V, Hannequin D, Lacomblez L, Le Ber I, Levy R, Michel BF, Pasquier F, Thomas-Anterion C, Pariente J, Sellal F, Vercelletto M, Benchetrit E, Bertin H, Bertrand A, Bissery A, Bombois S, Boncoeur MP, Cassagnaud P, Chastan M, Chen Y, Chupin M, Colliot O, Couratier P, Delbeucq X, Deramecourt V, Delmaire C, Gerardin E, Hossein-Foucher C, Dubois B, Habert MO, Hannequin D, Lautrette G, Lebouvier T, Le Ber I, Lehéricy S, Le Toullec B, Levy R, Martineau K, Mackowiak MA, Monteil J, Pasquier F, Petyt G, Pradat PF, Oya AH, Rinaldi D, Rollin-Sillaire A, Salachas F, Sayah S, Wallon D. Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriers. Neurobiol Aging 2019; 74:234.e1-234.e8. [DOI: 10.1016/j.neurobiolaging.2018.09.010] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 09/07/2018] [Accepted: 09/08/2018] [Indexed: 12/12/2022]
|
34
|
Casolla B, Caparros F, Cordonnier C, Bombois S, Hénon H, Bordet R, Orzi F, Leys D. Biological and imaging predictors of cognitive impairment after stroke: a systematic review. J Neurol 2018; 266:2593-2604. [PMID: 30350168 DOI: 10.1007/s00415-018-9089-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 10/07/2018] [Accepted: 10/08/2018] [Indexed: 12/29/2022]
Abstract
BACKGROUND Cognitive impairment is frequent after stroke, and several studies have suggested that biological and imaging characteristics present before stroke are associated with the development of post-stroke cognitive impairment. OBJECTIVE The aim of our study was to systematically review biological and imaging predictors of cognitive impairment after stroke. METHOD Studies were identified from bibliographic databases and reference lists, and were included if conducted in patients with acute stroke, with at least 30 patients, and a follow-up of at least 3 months. We included articles on potential biomarkers of cognitive impairment that pre-existed to stroke. RESULTS We identified 22,169 articles, including 20,349 with abstract. After analysis, 66 studies conducted in 42 cohorts met selection criteria. They included 30-9522 patients [median 170; interquartile range (IQR) 104-251] with a median follow-up of 12 months (IQR 3-36). All studies met quality criteria for description of the study population and standardization of biomarkers. Twenty-nine studies met all quality criteria. There was no convincing evidence that any biological marker may predict cognitive impairment. The most consistent predictors of cognitive impairment after stroke were global atrophy and medial temporal lobe atrophy. CONCLUSION Pre-existing cerebral atrophy is the most consistent predictor of cognitive impairment that can be identified in patients with an acute stroke.
Collapse
Affiliation(s)
- Barbara Casolla
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - François Caparros
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - Charlotte Cordonnier
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - Stéphanie Bombois
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - Hilde Hénon
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - Régis Bordet
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France
| | - Francesco Orzi
- Neurology Unit, NESMOS Department, Sapienza University of Rome, Rome, Italy
| | - Didier Leys
- Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Roger Salengro Hospital, University Lille, Inserm U1171, 59000, Lille, France.
| |
Collapse
|
35
|
Zietemann V, Georgakis MK, Dondaine T, Müller C, Mendyk AM, Kopczak A, Hénon H, Bombois S, Wollenweber FA, Bordet R, Dichgans M. Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke. Neurology 2018; 91:e1838-e1850. [PMID: 30333158 DOI: 10.1212/wnl.0000000000006506] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 08/01/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To examine whether the Montreal Cognitive Assessment (MoCA) administered within 7 days after stroke predicts long-term cognitive impairment, functional impairment, and mortality. METHODS MoCA was administered to 274 patients from 2 prospective hospital-based cohort studies in Germany (n = 125) and France (n = 149). Cognitive and functional outcomes were assessed at 6, 12, and 36 months after stroke by comprehensive neuropsychological testing, the Clinical Dementia Rating (CDR) scale, the modified Rankin Scale (mRS), and Instrumental Activities of Daily Living (IADL) and analyzed with generalized estimating equations. All-cause mortality was investigated by Cox proportional hazard models. Analyses were adjusted for demographic variables, education, vascular risk factors, premorbid cognitive status, and NIH Stroke Scale scores. The additive predictive value of MoCA was examined with receiver operating characteristic curves. RESULTS In pooled analyses, a baseline MoCA score <26 was associated with cognitive impairment, defined by neuropsychological testing (odds ratio [OR] 5.30, 95% confidence interval [CI] 2.75-10.22) and by CDR score ≥0.5 (OR 2.53, 95% CI 1.53-4.18); functional impairment, defined by mRS score >2 (OR 5.03, 95% CI 2.20-11.51) and by IADL score <8 (OR 2.48, 95% CI 1.40-4.38); and mortality (hazard ratio 7.24, 95% CI 1.99-26.35) across the 3-year follow-up. Patients with MoCA score <26 performed worse across all prespecified cognitive domains (executive function/attention, memory, language, visuospatial ability). MoCA increased the area under the curve for predicting cognitive impairment (neuropsychological testing 0.81 vs 0.72, p = 0.01) and functional impairment (mRS score >2, 0.88 vs 0.84, p = 0.047). CONCLUSION Early cognitive testing by MoCA predicts long-term cognitive outcome, functional outcome, and mortality after stroke. Our results support routine use of the MoCA in stroke patients.
Collapse
Affiliation(s)
- Vera Zietemann
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Marios K Georgakis
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Thibaut Dondaine
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Claudia Müller
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Anne-Marie Mendyk
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Anna Kopczak
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Hilde Hénon
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Stéphanie Bombois
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Frank Arne Wollenweber
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Régis Bordet
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany
| | - Martin Dichgans
- From the Institute for Stroke and Dementia Research (V.Z., M.K.G., C.M., A.K., F.A.W., M.D.), University Hospital, Ludwig-Maximilians-University, Munich, Germany; University of Lille (T.D., A.-M.M., H.H., S.B., R.B.), Inserm, CHU Lille, "Degenerative and Vascular Cognitive Disorders", Lille, France; German Centre for Neurodegenerative Diseases (M.D.); and Munich Cluster for Systems Neurology (M.D.), Germany.
| |
Collapse
|
36
|
Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Bombois S, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ 1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Front Aging Neurosci 2018; 10:297. [PMID: 30327597 PMCID: PMC6174237 DOI: 10.3389/fnagi.2018.00297] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Accepted: 09/10/2018] [Indexed: 12/23/2022] Open
Abstract
A combination of low cerebrospinal fluid (CSF) Amyloid β1–42 (Aβ1–42) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer’s disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ1–42; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer’s disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ1–42 on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers. Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT01315639.
Collapse
Affiliation(s)
- Emmanuelle Duron
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France.,APHP, Hôpital Paul Brousse, Service de Gériatrie du Dr Karoubi, Villejuif, France.,Université Paris-Sud 11, Centre de Recherche en Épidemiologie et Santé des Population- Depression et Antidépresseurs, INSERM UMR-1178, Le Kremlin-Bicêtre, France
| | - Jean-Sébastien Vidal
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Dominique Grousselle
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France
| | - Audrey Gabelle
- Memory Research and Resources Center, Gui de Chauliac Hospital, University of Montpellier, Montpellier, France
| | - Sylvain Lehmann
- Laboratoire de Biochimie Protéomique Clinique, CHU Montpellier, University of Montpellier, INSERM, Montpellier, France
| | - Florence Pasquier
- University of Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France
| | | | - Luc Buée
- University of Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France
| | - Bernadette Allinquant
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France
| | | | - Christiane Baret
- UF de Neurobiologie, Centre Biologie Pathologie du CHU-Lille, Lille, France
| | - Anne-Sophie Rigaud
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Hanon
- AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jacques Epelbaum
- Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France.,MECADEV UMR 7179 CNRS, Muséum National d'Histoire Naturelle, Paris, France
| |
Collapse
|
37
|
Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Bombois S, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Front Aging Neurosci 2018. [DOI: 10.3389/fnagi.2018.00297
expr 920238904 + 834128533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
|
38
|
Jaillard A, Vanhoutte M, Maureille A, Schraen S, Skrobala E, Delbeuck X, Rollin-Sillaire A, Pasquier F, Bombois S, Semah F. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease. Eur J Nucl Med Mol Imaging 2018; 46:324-333. [PMID: 30155553 DOI: 10.1007/s00259-018-4113-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 07/27/2018] [Indexed: 11/30/2022]
Abstract
PURPOSE One can reasonably suppose that cerebrospinal spinal fluid (CSF) biomarkers can identify distinct subgroups of Alzheimer's disease (AD) patients. In order to better understand differences in CSF biomarker patterns, we used FDG PET to assess cerebral metabolism in CSF-based subgroups of AD patients. METHODS Eighty-five patients fulfilling the criteria for probable early-onset AD (EOAD) underwent lumbar puncture, brain 18F-FDG PET and MRI. A cluster analysis was performed, with the CSF biomarkers for AD as variables. Vertex-wise, partial-volume-corrected metabolic maps were computed for the patients and compared between the clusters of patients. Linear correlations between each CSF biomarker and the metabolic maps were assessed. RESULTS Three clusters emerged. The "Aβ42" cluster contained 32 patients with low levels of Aβ42, while tau and p-tau remained within the normal range. The "Aβ42 + tau" cluster contained 41 patients with low levels of Aβ42 and high levels of tau and p-tau. Lastly, the "tau" cluster contained 12 patients with very high levels of tau and p-tau and low-normal levels of Aβ42. There were no inter-cluster differences in age, sex ratio, educational level, APOE genotype, disease duration or disease severity. The "Aβ42 + tau" and "tau" clusters displayed more marked frontal hypometabolism than the "Aβ42" cluster did, and frontal metabolism was significantly negatively correlated with the CSF tau level. The "Aβ42" and "Aβ42 + tau" clusters displayed more marked hypometabolism in the left occipitotemporal region than the "tau" cluster did, and metabolism in this region was significantly and positively correlated with the CSF Aβ42 level. CONCLUSION The CSF biomarkers can be used to identify metabolically distinct subgroups of patients with EOAD. Future research should seek to establish whether these biochemical differences have clinical consequences.
Collapse
Affiliation(s)
- Alice Jaillard
- Nuclear Medicine Department, CHU Lille, F-59000, Lille, France.
- Inserm, U1171, F-59000, Lille, France.
| | | | | | - Susanna Schraen
- Department of Biology and Pathology, CHU Lill, F-59000, Lille, France
| | | | | | | | - Florence Pasquier
- Inserm, U1171, F-59000, Lille, France
- Neurology Department, CHU Lille, F-59000, Lille, France
| | - Stéphanie Bombois
- Inserm, U1171, F-59000, Lille, France
- Neurology Department, CHU Lille, F-59000, Lille, France
| | - Franck Semah
- Nuclear Medicine Department, CHU Lille, F-59000, Lille, France
- Inserm, U1171, F-59000, Lille, France
| |
Collapse
|
39
|
Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tréluyer JM, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert PH, Godefroy O, Dantoine T, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimers Dement 2018; 14:858-868. [PMID: 29458036 DOI: 10.1016/j.jalz.2018.01.004] [Citation(s) in RCA: 87] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Revised: 12/01/2017] [Accepted: 01/08/2018] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Diagnostic relevance of plasma amyloid β (Aβ) for Alzheimer's disease (AD) process yields conflicting results. The objective of the study was to assess plasma levels of Aβ42 and Aβ40 in amnestic mild cognitive impairment (MCI), nonamnestic MCI, and AD patients and to investigate relationships between peripheral and central biomarkers. METHODS One thousand forty participants (417 amnestic MCI, 122 nonamnestic MCI, and 501 AD) from the Biomarker of AmyLoïd pepTide and AlZheimer's diseAse Risk multicenter prospective study with cognition, plasma, cerebrospinal fluid (CSF), and magnetic resonance imaging assessments were included. RESULTS Plasma Aβ1-42 and Aβ1-40 were lower in AD (36.9 [11.7] and 263 [80] pg/mL) than in amnestic MCI (38.2 [11.9] and 269 [68] pg/mL) than in nonamnestic MCI (39.7 [10.5] and 272 [52] pg/mL), respectively (P = .01 for overall difference between groups for Aβ1-42 and P = .04 for Aβ1-40). Globally, plasma Aβ1-42 correlated with age, Mini-Mental State Examination, and APOE ε4 allele. Plasma Aβ1-42 correlated with all CSF biomarkers in MCI but only with CSF Aβ42 in AD. DISCUSSION Plasma Aβ was associated with cognitive status and CSF biomarkers, suggesting the interest of plasma amyloid biomarkers for diagnosis purpose.
Collapse
Affiliation(s)
- Olivier Hanon
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| | - Jean-Sébastien Vidal
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Sylvain Lehmann
- Laboratoire de Protéomique Clinique, Department of Biochemistry, Saint Eloi Hospital, IRMB, Inserm U1183, Université de Montpellier, Montpellier, France
| | - Stéphanie Bombois
- Memory Clinic, CHU Lille, Lille, France; Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, Lille, France
| | | | - Jean-Marc Tréluyer
- Unité de recherche Clinique, Hôpital Universitaire Necker-Enfants Malades, APHP, Université Paris Descartes, Paris, France
| | - Patrick Gelé
- Department of Biology and Pathology, CHU de Lille, Lille, France; Université Lille, INSERM UMRS 1172, Alzheimer's & Tauopathies, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France
| | - Christine Delmaire
- Memory Clinic, CHU Lille, Lille, France; Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Fredéric Blanc
- Memory Resource and Research Centre of Strasbourg/Colmar, CHRU de Strasbourg, Strasbourg, France; University of Strasbourg and French National Centre for Scientific Research (CNRS), ICube Laboratory and Fédération de Médecine Translationnelle de Strasbourg (FMTS), Team Imagerie Multimodale Intégrative en Santé (IMIS)/Neurocrypto, Strasbourg, France
| | - Jean-François Mangin
- CATI Multicenter Neuroimaging Platform, Neurospin, CEA, cati-neuroimaging.com, Paris Saclay University, Gif-sur-Yvette, France
| | - Luc Buée
- Department of Biology and Pathology, CHU de Lille, Lille, France; Université Lille, INSERM UMRS 1172, Alzheimer's & Tauopathies, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France
| | - Jacques Touchon
- Memory Resource and Research Centre of Montpellier, Department of Neurology, CHU Gui de Chauliac, Université de Montpellier, Montpellier, France
| | - Jacques Hugon
- Memory Resource and Research Centre of Paris Nord-Ile de France, Groupe Hospitalier Saint Louis-Lariboisière-Fernand Widal, APHP, Paris, France; University of Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Bruno Vellas
- Memory Resource and Research Centre of Midi-Pyrénées, CHU La Grave-Casselardit, Toulouse, France
| | - Evelyne Galbrun
- Department of Gérontology 2, Centre Hospitalier Émile-Roux, AP-HP, Limeil-Brévannes, France
| | - Athanase Benetos
- Memory Resource and Research Centre of Lorraine, CHU de Nancy, Nancy, France
| | - Gilles Berrut
- Memory Research Resource Center of Nantes, CHU de Nantes, Nantes, France
| | - Elèna Paillaud
- Department of Internal Medicine and Geriatrics, Hôpital Henri-Mondor, APHP, Créteil, France
| | - David Wallon
- Memory Resource and Research Centre of Haute-Normandie, CHU Charles Nicolle, Rouen, France; Inserm U1079, IRIB, Université de Rouen-Normandie, Rouen, France
| | | | | | - Marc Paccalin
- Memory Resource and Research Centre of Poitiers, CHU de Poitiers, Poitiers, France
| | | | - Olivier Godefroy
- Memory Resource and Research Centre of Amiens Picardie, CHU d'Amiens-Picardie, Amiens, France
| | - Thierry Dantoine
- Memory Research Resource Center of Limoges, CHU de Limoges, Limoges, France
| | - Vincent Camus
- Memory Resource and Research Centre of Tours, CHRU de Tours, Tours, France; Inserm U930 Imagerie et Cerveau, Université François-Rabelais de Tours, Tours, France
| | - Joël Belmin
- Service de Gériatrie à orientation Cardiologique et Neurologique, Hôpitaux Universitaires Pitie-Salpêtrière-Charles Foix, APHP, Paris, France; DHU FAST, Sorbonne Universités, UPMC Université Paris 06, Paris, France
| | - Pierre Vandel
- Memory Resource and Research Centre of Besançon-Franche-Comté, CHU de Besançon, Besançon, France; EA 481 Neuroscience, IFR 133, University of Bourgogne Franche-Comté, Besançon, France
| | - Jean-Luc Novella
- Memory Resource and Research Centre of Champagne Ardenne, CHU de Reims, Reims, France; EA 3797, Université de Reims Champagne Ardenne, Reims, France
| | - Emmanuelle Duron
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Anne-Sophie Rigaud
- Memory Resource and Research Centre of de Paris-Broca-Ile de France, Hopital Broca, APHP, Paris, France; EA 4468, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Suzanna Schraen-Maschke
- Department of Biology and Pathology, CHU de Lille, Lille, France; Université Lille, INSERM UMRS 1172, Alzheimer's & Tauopathies, Centre de Biologie Pathologie Génétique, CHU Lille, Lille, France
| | - Audrey Gabelle
- Memory Resource and Research Centre of Montpellier, Department of Neurology, CHU Gui de Chauliac, Université de Montpellier, Montpellier, France
| | | |
Collapse
|
40
|
Ceccaldi M, Jonveaux T, Verger A, Krolak‐Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert M, Wallon D, Chastan M, Payoux P, Ceccaldi M, Guedj E, Ceccaldi M, Felician O, Didic M, Gueriot C, Koric L, Kletchkova‐Gantchev R, Guedj E, Godefroy O, Andriuta D, Devendeville A, Dupuis D, Binot I, Barbay M, Meyer M, Moullard V, Magnin E, Chamard L, Haffen S, Morel O, Drouet C, Boulahdour H, Goas P, Querellou‐Lefranc S, Sayette V, Cogez J, Branger P, Agostini D, Manrique A, Rouaud O, Bejot Y, Jacquin‐Piques A, Dygai‐Cochet I, Berriolo‐Riedinger A, Moreaud O, Sauvee M, Crépin CG, Pasquier F, Bombois S, Lebouvier T, Mackowiak‐Cordoliani M, Deramecourt V, Rollin‐Sillaire A, Cassagnaud‐Thuillet P, Chen Y, Semah F, Petyt G, Krolak‐Salmon P, Federico D, Danaila KL, Guilhermet Y, Magnier C, Makaroff Z, Rouch I, Xie J, Roubaud C, Coste M, David K, Sarciron A, Waissi AS, Scheiber C, Houzard C, Gabelle‐Deloustal A, Bennys K, Marelli C, Touati L, Mariano‐Goulart D, Verbizier‐Lonjon D, Jonveaux T, Benetos A, Kearney‐Schwartz A, Perret‐Guillaume C, Verger A, Vercelletto M, Boutoleau‐Bretonniere C, Pouclet‐Courtemanche H, Wagemann N, Pallardy A, Hugon J, Paquet C, Dumurgier J, Millet P, Queneau M, Dubois B, Epelbaum S, Levy M, Habert M, Novella J, Jaidi Y, Papathanassiou D, Morland D, Belliard S, Salmon A, Lejeune F, Hannequin D, Wallon D, Martinaud O, Zarea A, Chastan M, Pariente J, Thalamas C, Galitzky‐Gerber M, Tricoire Ricard A, Calvas F, Rigal E, Payoux P, Hitzel A, Delrieu J, Ousset P, Lala F, Sastre‐Hengan N, Stephens A, Guedj E. Added value of
18
F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimers Dement 2017; 14:293-305. [DOI: 10.1016/j.jalz.2017.09.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 08/29/2017] [Accepted: 09/06/2017] [Indexed: 11/25/2022]
Affiliation(s)
- Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- Geriatric Department CHRU de Nancy–Hôpital Brabois Vandoeuvre‐les‐Nancy France
| | - Antoine Verger
- INSERM U947 Unité d'Imagerie Adaptative Diagnostique et Interventionnelle Nancy France
| | - Pierre Krolak‐Salmon
- Clinical and Research Memory Center of Lyon Hospices civils de Lyon, Université Claude Bernard Lyon 1 Inserm 1028 Lyon France
| | | | - Olivier Godefroy
- Neurology Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Trevor Shields
- Nuclear Medicine Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Audrey Perrotin
- Piramal Imaging Clinical Research and Development Berlin Germany
| | | | - Santiago Bullich
- AP‐HP–Hôpital Pitié Salpétrière Memory and Alzheimer Disease Institute IM2A Paris France
| | - Aleksandar Jovalekic
- Laboratoire d'Imagerie Biomédicale Sorbonne Universités, UPMC Univ Paris 06, Inserm U 1146, CNRS UMR 7371 Paris France
| | - Nicola Raffa
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Odile Habert
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Felician
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mira Didic
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claude Gueriot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lejla Koric
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Radka Kletchkova‐Gantchev
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Godefroy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Daniela Andriuta
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Devendeville
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Diane Dupuis
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ingrid Binot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mélanie Barbay
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marc‐Etienne Meyer
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Véronique Moullard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eloi Magnin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ludivine Chamard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Sophie Haffen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Morel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Clément Drouet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hatem Boulahdour
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Philippe Goas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Solène Querellou‐Lefranc
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Sayette
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Cogez
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Branger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Agostini
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Manrique
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Rouaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yannick Bejot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Jacquin‐Piques
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Inna Dygai‐Cochet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alina Berriolo‐Riedinger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Moreaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathilde Sauvee
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Céline Gallazzani Crépin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphanie Bombois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thibaud Lebouvier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Anne Mackowiak‐Cordoliani
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Deramecourt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Adeline Rollin‐Sillaire
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascaline Cassagnaud‐Thuillet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yaohua Chen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Grégory Petyt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Krolak‐Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Federico
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Keren Liora Danaila
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yves Guilhermet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christophe Magnier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Zaza Makaroff
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Isabelle Rouch
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jing Xie
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Caroline Roubaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Hélène Coste
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Kenny David
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Sarciron
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aziza Sediq Waissi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christian Scheiber
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Houzard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Audrey Gabelle‐Deloustal
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Karim Bennys
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Cecilia Marelli
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lynda Touati
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Mariano‐Goulart
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Delphine Verbizier‐Lonjon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Athanase Benetos
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anna Kearney‐Schwartz
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christine Perret‐Guillaume
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Antoine Verger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Martine Vercelletto
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Boutoleau‐Bretonniere
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hélène Pouclet‐Courtemanche
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Wagemann
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Amandine Pallardy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jacques Hugon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Paquet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Dumurgier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascal Millet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Queneau
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphane Epelbaum
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marcel Levy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Jean‐Luc Novella
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yacine Jaidi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Dimitri Papathanassiou
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Serge Belliard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Lejeune
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Didier Hannequin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Martinaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aline Zarea
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Claire Thalamas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | | | - Fabienne Calvas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Emilie Rigal
- ToNIC, Toulouse NeuroImaging Center Université de Toulouse, Inserm, UPS Toulouse France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Hitzel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Delrieu
- Neurology Department CHU de Rouen–Hôpital Charles Nicolle Rouen France
| | - Pierre‐Jean Ousset
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Françoise Lala
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Sastre‐Hengan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Andrew Stephens
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Nuclear Medicine Department Aix‐Marseille University, CERIMED, CNRS, INT, Institut de Neurosciences de la Timone Marseille France
| | | |
Collapse
|
41
|
Delattre C, Bournonville C, Auger F, Lopes R, Delmaire C, Henon H, Mendyk AM, Bombois S, Devedjian JC, Leys D, Cordonnier C, Bordet R, Bastide M. Hippocampal Deformations and Entorhinal Cortex Atrophy as an Anatomical Signature of Long-Term Cognitive Impairment: from the MCAO Rat Model to the Stroke Patient. Transl Stroke Res 2017; 9:294-305. [PMID: 29034421 DOI: 10.1007/s12975-017-0576-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Revised: 10/02/2017] [Accepted: 10/05/2017] [Indexed: 12/17/2022]
Abstract
Stroke patients have an elevated risk of developing long-term cognitive disorders or dementia. The latter is often associated with atrophy of the medial temporal lobe. However, it is not clear whether hippocampal and entorhinal cortex atrophy is the sole predictor of long-term post-stroke dementia. We hypothesized that hippocampal deformation (rather than atrophy) is a predictive marker of long-term post-stroke dementia on a rat model and tested this hypothesis in a prospective cohort of stroke patients.Male Wistar rats were subjected to transient middle cerebral artery occlusion and assessed 6 months later. Ninety initially dementia-free patients having suffered a first-ever ischemic stroke were prospectively included in a clinical study. In the rat model, significant impairments in hippocampus-dependent memories were observed. MRI studies did not reveal significant atrophy of the hippocampus volume, but significant deformations were indeed observed-particularly on the ipsilateral side. There, the neuronal surface area was significantly lower in ischemic rats and was associated with a lower tissue density and a markedly thinner entorhinal cortex. At 6 months post-stroke, 49 of the 90 patients displayed cognitive impairment (males 55.10%). Shape analysis revealed marked deformations of their left hippocampus, a significantly lower entorhinal cortex surface area, and a wider rhinal sulcus but no hippocampal atrophy. Hence, hippocampal deformations and entorhinal cortex atrophy were associated with long-term impaired cognitive abilities in a stroke rat model and in stroke patients. When combined with existing biomarkers, these markers might constitute sensitive new tools for the early prediction of post-stroke dementia.
Collapse
Affiliation(s)
- C Delattre
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - C Bournonville
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - F Auger
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - R Lopes
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - C Delmaire
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - H Henon
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - A M Mendyk
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - S Bombois
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - J C Devedjian
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - D Leys
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | - C Cordonnier
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France
| | | | - M Bastide
- U1171 - Degenerative & Vascular Cognitive Disorders, Université Lille, INSERM, CHU Lille, Université du Littoral Côte d'Opale, 59000, Lille, France.
- U1171 - Degenerative & Vascular Cognitive Disorders, Faculté de Médecine, Université Lille, INSERM, CHU Lille, 1 place de Verdun, 59045, Lille cedex, France.
| |
Collapse
|
42
|
Magnin E, Dumurgier J, Bouaziz-Amar E, Bombois S, Wallon D, Gabelle A, Lehmann S, Blanc F, Bousiges O, Hannequin D, Jung B, Miguet-Alfonsi C, Quillard M, Pasquier F, Peoc’h K, Laplanche JL, Hugon J, Paquet C. Les biomarqueurs du liquide cérébro-spinal dans la maladie d’Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes. Rev Med Interne 2017; 38:250-255. [DOI: 10.1016/j.revmed.2016.10.383] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 07/19/2016] [Accepted: 10/18/2016] [Indexed: 01/08/2023]
|
43
|
Sachdev PS, Lo JW, Crawford JD, Mellon L, Hickey A, Williams D, Bordet R, Mendyk AM, Gelé P, Deplanque D, Bae HJ, Lim JS, Brodtmann A, Werden E, Cumming T, Köhler S, Verhey FRJ, Dong YH, Tan HH, Chen C, Xin X, Kalaria RN, Allan LM, Akinyemi RO, Ogunniyi A, Klimkowicz-Mrowiec A, Dichgans M, Wollenweber FA, Zietemann V, Hoffmann M, Desmond DW, Linden T, Blomstrand C, Fagerberg B, Skoog I, Godefroy O, Barbay M, Roussel M, Lee BC, Yu KH, Wardlaw J, Makin SJ, Doubal FN, Chappell FM, Srikanth VK, Thrift AG, Donnan GA, Kandiah N, Chander RJ, Lin X, Cordonnier C, Moulin S, Rossi C, Sabayan B, Stott DJ, Jukema JW, Melkas S, Jokinen H, Erkinjuntti T, Mok VCT, Wong A, Lam BYK, Leys D, Hénon H, Bombois S, Lipnicki DM, Kochan NA. STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimers Dement (Amst) 2016; 7:11-23. [PMID: 28138511 PMCID: PMC5257024 DOI: 10.1016/j.dadm.2016.10.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
INTRODUCTION The Stroke and Cognition consortium (STROKOG) aims to facilitate a better understanding of the determinants of vascular contributions to cognitive disorders and help improve the diagnosis and treatment of vascular cognitive disorders (VCD). METHODS Longitudinal studies with ≥75 participants who had suffered or were at risk of stroke or TIA and which evaluated cognitive function were invited to join STROKOG. The consortium will facilitate projects investigating rates and patterns of cognitive decline, risk factors for VCD, and biomarkers of vascular dementia. RESULTS Currently, STROKOG includes 25 (21 published) studies, with 12,092 participants from five continents. The duration of follow-up ranges from 3 months to 21 years. DISCUSSION Although data harmonization will be a key challenge, STROKOG is in a unique position to reuse and combine international cohort data and fully explore patient level characteristics and outcomes. STROKOG could potentially transform our understanding of VCD and have a worldwide impact on promoting better vascular cognitive outcomes.
Collapse
Affiliation(s)
- Perminder S Sachdev
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia; Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia
| | - Jessica W Lo
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia
| | - John D Crawford
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia
| | - Lisa Mellon
- Department of Psychology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Anne Hickey
- Department of Psychology, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - David Williams
- Department of Stroke and Geriatric Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Régis Bordet
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Anne-Marie Mendyk
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Patrick Gelé
- University of Lille, Inserm, CHU Lille, CIC 1403 - Centre d'investigation clinique, Lille, France
| | - Dominique Deplanque
- University of Lille, Inserm, CHU Lille, CIC 1403 - Centre d'investigation clinique, Lille, France
| | - Hee-Joon Bae
- Department of Neurology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Jae-Sung Lim
- Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
| | - Amy Brodtmann
- Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - Emilio Werden
- Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - Toby Cumming
- Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - Sebastian Köhler
- School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
| | - Frans R J Verhey
- School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
| | - Yan-Hong Dong
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia; Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia; Memory Ageing and Cognition Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Medicine (Neurology Division), Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Hui Hui Tan
- Memory Ageing and Cognition Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Medicine (Neurology Division), Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Christopher Chen
- Memory Ageing and Cognition Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Xu Xin
- Memory Ageing and Cognition Center, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
| | - Raj N Kalaria
- Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - Louise M Allan
- Neurovascular Research Group, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - Rufus O Akinyemi
- Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Adesola Ogunniyi
- Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training College of Medicine, University of Ibadan, Ibadan, Nigeria; Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | | | - Martin Dichgans
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Frank A Wollenweber
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Vera Zietemann
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany
| | - Michael Hoffmann
- Cognitive Neurology and Stroke Programs, University of Central Florida, Orlando VA Medical Center, Orlando, Florida, USA
| | | | - Thomas Linden
- Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia; Institute of Neuroscience and Physiology, Centre of Brain Research and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Christian Blomstrand
- Institute of Neuroscience and Physiology, Centre of Brain Research and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Björn Fagerberg
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory for Cardiovascular and Metabolic Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Ingmar Skoog
- Institute of Neuroscience and Physiology, Center for Health and Ageing AGECAP, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Olivier Godefroy
- Department of Neurology and Laboratory of Functional Neurosciences, University Hospital of Amiens, France
| | - Mélanie Barbay
- Department of Neurology and Laboratory of Functional Neurosciences, University Hospital of Amiens, France
| | - Martine Roussel
- Department of Neurology and Laboratory of Functional Neurosciences, University Hospital of Amiens, France
| | - Byung-Chul Lee
- Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
| | - Kyung-Ho Yu
- Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
| | - Joanna Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Stephen J Makin
- Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK
| | - Fergus N Doubal
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Velandai K Srikanth
- Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, Australia; Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
| | - Amanda G Thrift
- Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea; Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, Australia
| | - Geoffrey A Donnan
- Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | | | | | - Xuling Lin
- Department of Neurology, National Neuroscience Institute, Singapore
| | - Charlotte Cordonnier
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Solene Moulin
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Costanza Rossi
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Behnam Sabayan
- Department of Gerontology and Geriatrics, Leiden University Medical Centre, Leiden, the Netherlands
| | - David J Stott
- Academic Section of Geriatrics, University of Glasgow, Glasgow, United Kingdom
| | - J Wouter Jukema
- Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Susanna Melkas
- Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland
| | - Hanna Jokinen
- Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland
| | - Timo Erkinjuntti
- Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland
| | - Vincent C T Mok
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; Therese Pei Fong Chow Research Centre for Prevention of Dementia, Hong Kong SAR, China
| | - Adrian Wong
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; Therese Pei Fong Chow Research Centre for Prevention of Dementia, Hong Kong SAR, China
| | - Bonnie Y K Lam
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; Therese Pei Fong Chow Research Centre for Prevention of Dementia, Hong Kong SAR, China
| | - Didier Leys
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Hilde Hénon
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Stéphanie Bombois
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative & Vascular Cognitive Disorders, Lille, France
| | - Darren M Lipnicki
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia
| | - Nicole A Kochan
- Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia
| | | |
Collapse
|
44
|
Moulin S, Leys D, Bombois S, Cordonnier C. Cognitive status after intracerebral haemorrhage – Authors' reply. Lancet Neurol 2016; 15:1206-1207. [DOI: 10.1016/s1474-4422(16)30239-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Revised: 09/12/2016] [Accepted: 09/12/2016] [Indexed: 11/29/2022]
|
45
|
Moulin S, Labreuche J, Bombois S, Rossi C, Boulouis G, Hénon H, Duhamel A, Leys D, Cordonnier C. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016; 15:820-829. [PMID: 27133238 DOI: 10.1016/s1474-4422(16)00130-7] [Citation(s) in RCA: 152] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Revised: 02/18/2016] [Accepted: 03/11/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Dementia occurs in at least 10% of patients within 1 year after stroke. However, the risk of dementia after spontaneous intracerebral haemorrhage that accounts for about 15% of all strokes has not been investigated in prospective studies. We aimed to determine the incidence of dementia and risk factors after an intracerebral haemorrhage. METHODS We did a prospective observational cohort study in patients with spontaneous intracerebral haemorrhage from the Prognosis of Intracerebral Haemorrhage (PITCH) cohort who were admitted to Lille University Hospital, Lille, France. We included patients aged 18 years and older with parenchymal haemorrhage on the first CT scan. Exclusion criteria were pure intraventricular haemorrhage; intracerebral haemorrhage resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma, or tumour; haemorrhagic transformation within an infarct; and referral from other hospitals. Median follow-up was 6 years. We studied risk factors (clinical and neuroradiological [MRI] biomarkers) of new-onset dementia as per a prespecified subgroup analysis, according to intracerebral haemorrhage location. Dementia diagnosis was based on the National Institute on Aging-Alzheimer's Association criteria for all-cause dementia. We did multivariable analyses using competing risk analyses, with death during follow-up as a competing event. FINDINGS From the 560 patients with spontaneous intracerebral haemorrhage enrolled in the PITCH cohort between Nov 3, 2004 and March 29, 2009, we included 218 patients (median age 67·5 years) without pre-existing dementia who were alive at 6 months follow-up. 63 patients developed new-onset dementia leading to an incidence rate of 14·2% (95% CI 10·0-19·3) at 1 year after intracerebral haemorrhage, and incidence reached 28·3% (22·4-34·5) at 4 years. The incidence of new-onset dementia was more than two times higher in patients with lobar intracerebral haemorrhage (incidence at 1 year 23·4%, 14·6-33·3) than for patients with non-lobar intracerebral haemorrhage (incidence at 1 year 9·2%, 5·1-14·7). Disseminated superficial siderosis (subhazard ratio [SHR] 7·45, 95% CI 4·27-12·99), cortical atrophy score (SHR per 1-point increase 2·61, 1·70-4·01), a higher number of cerebral microbleeds (SHR for >5 cerebral microbleeds 2·33, 1·38-3·94), and older age (SHR per 10-year increase 1·34, 1·00-1·79) were risk factors of new-onset dementia. INTERPRETATION There is a substantial risk of incident dementia in dementia-free survivors of spontaneous intracerebral haemorrhage; our results suggest that underlying cerebral amyloid angiopathy is a contributing factor to the occurrence of new-onset dementia. Future clinical trials including patients with intracerebral haemorrhage should assess cognitive endpoints. FUNDING French Ministry of Education, Research, and Technology, Adrinord, Inserm U1171.
Collapse
Affiliation(s)
- Solène Moulin
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France
| | - Julien Labreuche
- Université Lille, EA 2694, CHU Lille, Department of Biostatics and Public Health, Lille, France
| | - Stéphanie Bombois
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France
| | - Costanza Rossi
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France
| | - Gregoire Boulouis
- Massachusetts General Hospital, Stroke Research Center, Boston, MA, USA
| | - Hilde Hénon
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France
| | - Alain Duhamel
- Université Lille, EA 2694, CHU Lille, Department of Biostatics and Public Health, Lille, France
| | - Didier Leys
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France
| | - Charlotte Cordonnier
- Université Lille, Inserm U1171, Degenerative and Vascular Cognitive Disorders, CHU Lille, Department of Neurology, Lille, France.
| |
Collapse
|
46
|
Grangeon L, Paquet C, Bombois S, Maltete D, Didier H, Wallon D. Démence et protéine Tau élevée : quels diagnostics craindre ? Rev Neurol (Paris) 2016. [DOI: 10.1016/j.neurol.2016.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
47
|
Moulin S, Labreuche J, Bombois S, Rossi C, Hénon H, Leys D, Cordonnier C. Démence post-hémorragie intracérébrale : étude prospective de cohorte observationnelle. Rev Neurol (Paris) 2016. [DOI: 10.1016/j.neurol.2016.01.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Rollin-Sillaire A, Bombois S, Mackowiak MA, Chen Y, Maurage CA, Pasquier F, Deramecourt V. Cohorte lilloise de malades Alzheimer jeunes (COMAJ) : premières données neuropathologiques post-mortem. Rev Neurol (Paris) 2016. [DOI: 10.1016/j.neurol.2016.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
49
|
Moulin S, Labreuche J, Rossi C, Boulouis G, Bombois S, Hénon H, Leys D, Cordonnier C. Abstract 43: Dementia After Spontaneous Intra-cerebral Hemorrhage. Stroke 2016. [DOI: 10.1161/str.47.suppl_1.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Stroke and dementia are closely related but no prospective study ever focused on dementia in patients with intracerebral hemorrhage (ICH).
Objective:
To determine incidence, prognostic factors and possible mechanisms of post-ICH dementia in a large population of non-demented ICH patients over a long period of follow-up.
Methods:
Prospective cohort of consecutive adults with spontaneous ICH. Patients free of dementia and alive at 6 months were included. We studied clinical and neuroradiological (MRI) biomarkers with a prespecified subgroup analysis according to ICH location. Age-adjusted analyses were used to select variables (p<0.1) included in multivariable models that took into account death as competing risk.
Results:
In a cohort of 218 ICH patients (108 males; median age 67.5, interquartile range (IQR) 55-76), 63 patients developed new onset dementia during a median follow-up of 5.4 years (IQR, 4.2-5.8). At 1 year after ICH, the overall incidence of dementia was 20% (95% CI 15-25). It differed between lobar ICH (n=77, 30% 95% CI 20-40) and non lobar ICH (n=141, 16% 95% CI 10-22). Prognostic factors of new onset dementia were lobar Iocation (Hazard Ratio (HR): 2.21; 95% CI 1.30-3.79), older age (HR: 1.06 per year; 95% CI 1.03-1.09), history of previous stroke or transient ischemic attack (HR: 2.56; 95% CI 1.42-4.61), higher NIHSS (HR: 1.03 per year; 95% CI 1.01-1.06), severe leucoaraïosis (HR: 2.87; 95% CI 1.63-5.07) and recurrent stroke during follow-up (HR: 3.22; 95% CI 1.27-8.15). Prognostic neuroradiological biomarkers were increasing cortical atrophy (HR: 2.7; 95% CI 1.7-4.3), presence of disseminated superficial siderosis (HR: 7.10; 95% CI 3.93-12.83), higher number of lobar cerebral microbleeds (HR: 3.40; 95%CI 1.87-6.18). Among lobar ICH, superficial siderosis was a strong predictor (HR: 6.74; 95% CI 3.32-13.68).
Conclusion:
The incidence of new onset dementia is high after ICH with a strong influence of lobar location. Among patients with lobar ICH, prognostic factors suggested a strong implication of underlying cerebral amyloid angiopathy that might predict future risk of dementia. Results of our study suggest that all prognostic factors of dementia are already present before the ICH occurs.
Collapse
|
50
|
Chen Y, Hénon H, Bombois S, Pasquier F, Cordonnier C. Multiple Simultaneous Spontaneous Intracerebral Hemorrhages: A Rare Entity. Cerebrovasc Dis 2015; 41:74-9. [DOI: 10.1159/000442475] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Accepted: 11/09/2015] [Indexed: 11/19/2022] Open
Abstract
Background: In hospital databases, multiple simultaneous spontaneous intracerebral hemorrhages (ICH-m) account for 0.7-5.6% of all ICHs. Their long-term outcome has never been systematically and prospectively investigated. We aimed at identifying the long-term outcome of patients with ICH-m. Methods: We prospectively recruited consecutive adults with ICH-m and followed them up for at least 4.5 years. We classified patients into the following 3 groups: (i) definite or probable cerebral amyloid angiopathy (CAA), (ii) deep perforating vasculopathy (DPV) and (iii) unknown causes. Results: Of 562 consecutive patients with ICH, 32 had ICH-m (5.7%): 8 (25%) with probable CAA, 5 (16%) with DPV and 19 (59%) with ICH-m of undetermined cause. At the last visit (cumulative follow-up of 39.5 person-year), 27 patients (84%) had died, and 3 of the 5 survivors were independent. Late-onset seizures, recurrent ICH-m (symptomatic or not) and new brain microbleeds were mainly found in patients with probable CAA. Conclusions: ICH-m is a rare but extremely severe expression of ICH. Survivors with CAA are more likely to develop late seizures and new hemorrhagic lesions. Because of low survival rates, large multicenter cohort studies are needed for a better understanding of this rare condition.
Collapse
|